Microarray analysis of bone marrow-derived macrophage cells treated with Kdo2-lipid A (KLA) and ATP

Search by fold change ratio | Search by KEGG pathway | Search by LIPID MAPS lipid pathway

Kdo2-Lipid A / ATP gene array data - treatment:control ratios

KEGG pathway: Proteoglycans in cancer (mmu05205)

Legend:graph_icon: View data/graphs for replicates
Gene symbol    Time course plot Accession Description Treatment 15min 30min 1hr 2hr 4hr 8hr 20hr
Actb
KLA  ATP  ATP+KLA
 BC016624 cDNA clone IMAGE:4501052 [BC016624] KLA 1.20 1.20 1.19 1.73 1.83 2.52 1.70
ATP 1.04 1.01 1.03 .92 1.07 .66 .91
KLA/ATP 1.34 1.40 1.69 1.28 1.27 1.19 1.06
Actb
KLA  ATP  ATP+KLA
 NM_007393 actin, beta, cytoplasmic (Actb), mRNA [NM_007393] KLA 1.58 1.64 1.59 2.02 2.03 3.04 1.75
ATP 1.00 .95 1.26 1.18 1.33 .86 .91
KLA/ATP 1.52 1.75 2.42 1.92 2.17 1.54 1.28
Actg1
KLA  ATP  ATP+KLA
 NM_009609 actin, gamma, cytoplasmic 1 (Actg1), mRNA [NM_009609] KLA 1.02 1.03 1.34 1.07 1.49 1.58 .71
ATP 1.07 1.24 .76 .76 .63 .46 .78
KLA/ATP 1.20 1.30 .75 .82 .60 .53 .55
AK019932
KLA  ATP  ATP+KLA
 AK019932 adult male pituitary gland cDNA, RIKEN full-length enriched library, clone:5330434N09 product:inferred: transmembrane receptor frizzled 5 {Mus musculus}, full insert sequence [AK019932] KLA .99 .94 .97 .98 .96 .99 1.03
ATP 1.02 1.07 1.02 .97 1.00 .98 .93
KLA/ATP .93 .99 .91 1.04 1.02 1.01 1.00
Akt1
KLA  ATP  ATP+KLA
 NM_009652 thymoma viral proto-oncogene 1 (Akt1), mRNA [NM_009652] KLA .80 .80 .75 .75 .71 .70 .82
ATP 1.00 1.02 .76 .85 .76 .68 .84
KLA/ATP .82 .80 .64 .68 .67 .61 .72
Akt2
KLA  ATP  ATP+KLA
 NM_007434 thymoma viral proto-oncogene 2 (Akt2), transcript variant 2, mRNA [NM_007434] KLA 1.45 1.49 1.81 1.61 1.83 1.17 .92
ATP 1.12 1.12 1.00 1.28 1.20 .94 1.06
KLA/ATP 1.48 1.70 1.69 1.58 1.57 1.32 1.27
Akt3
KLA  ATP  ATP+KLA
 NM_011785 thymoma viral proto-oncogene 3 (Akt3), mRNA [NM_011785] KLA 3.42 3.45 5.31 5.16 4.65 3.80 2.12
ATP 1.12 1.22 1.10 1.37 1.02 1.11 1.56
KLA/ATP 3.72 4.17 4.62 4.64 2.74 2.05 3.82
Ank1
KLA  ATP  ATP+KLA
 NM_031158 ankyrin 1, erythroid (Ank1), transcript variant 2, mRNA [NM_031158] KLA .95 .91 .92 .91 .91 .94 1.11
ATP 1.01 1.01 1.01 .96 .87 .84 1.00
KLA/ATP .93 .92 .92 .92 .85 .85 .92
Ank2
KLA  ATP  ATP+KLA
 AK047866 16 days embryo head cDNA, RIKEN full-length enriched library, clone:C130016P21 product:unclassifiable, full insert sequence. [AK047866] KLA .98 .94 .99 1.00 1.05 .98 1.02
ATP .97 .91 .97 1.02 1.07 1.02 1.01
KLA/ATP 1.02 .97 .96 1.01 1.08 1.05 1.06
Ank2
KLA  ATP  ATP+KLA
 NM_178655 ankyrin 2, brain (Ank2), transcript variant 2, mRNA [NM_178655] KLA 1.03 .96 1.00 .92 .97 .90 .86
ATP .98 1.01 .98 .97 .94 1.04 .99
KLA/ATP .94 .91 .91 .89 .89 .99 .86
Ank3
KLA  ATP  ATP+KLA
 NM_146005 ankyrin 3, epithelial (Ank3), transcript variant 2, mRNA [NM_146005] KLA .97 1.03 1.11 1.00 1.05 1.02 1.03
ATP 1.00 1.00 1.06 1.03 1.01 .98 .96
KLA/ATP 1.01 .98 1.00 .99 1.00 1.06 .94
Araf
KLA  ATP  ATP+KLA
 NM_009703 v-raf murine sarcoma 3611 viral oncogene homolog (Araf), mRNA [NM_009703] KLA .87 .80 .89 .93 1.10 1.19 1.16
ATP 1.09 1.11 1.19 1.18 .78 .53 1.18
KLA/ATP 1.00 .95 .99 .93 .63 .55 1.27
Arhgef1
KLA  ATP  ATP+KLA
 NM_008488 Rho guanine nucleotide exchange factor (GEF) 1 (Arhgef1), mRNA [NM_008488] KLA .80 .82 .80 .56 .66 .74 .85
ATP 1.19 1.53 .87 1.47 .87 .55 .84
KLA/ATP 1.07 .88 .51 .99 .50 .58 .65
Arhgef12
KLA  ATP  ATP+KLA
 NM_027144 Rho guanine nucleotide exchange factor (GEF) 12 (Arhgef12), mRNA [NM_027144] KLA 1.01 .94 .89 .87 .84 .81 .80
ATP 1.05 .94 1.09 .77 .60 .86 .78
KLA/ATP .93 .88 .86 .70 .52 .66 .58
BC010335
KLA  ATP  ATP+KLA
 BC010335 fibronectin 1, mRNA (cDNA clone IMAGE:3156499), **** WARNING: chimeric clone ****. [BC010335] KLA .94 .88 1.01 .99 .95 .95 1.07
ATP 1.06 .98 1.20 1.30 1.07 .97 .97
KLA/ATP .93 1.00 1.07 1.20 1.02 .96 .94
Braf
KLA  ATP  ATP+KLA
 NM_139294 Braf transforming gene (Braf), mRNA [NM_139294] KLA 1.52 1.57 1.55 1.33 1.83 1.52 1.60
ATP 1.08 1.17 1.02 1.37 .95 1.15 .95
KLA/ATP 1.64 1.69 1.39 1.51 1.04 1.31 1.26
Camk2a
KLA  ATP  ATP+KLA
 NM_177407 calcium/calmodulin-dependent protein kinase II alpha (Camk2a), transcript variant 2, mRNA [NM_177407] KLA .98 .97 .98 .95 .97 1.02 .97
ATP .98 1.11 1.02 .89 .94 .89 .82
KLA/ATP .99 .95 1.02 .88 .88 .87 .87
Camk2b
KLA  ATP  ATP+KLA
 NM_007595 calcium/calmodulin-dependent protein kinase II, beta (Camk2b), mRNA [NM_007595] KLA 1.09 1.28 1.42 1.41 1.37 1.24 .68
ATP .94 .87 .95 .91 .67 .44 .48
KLA/ATP 1.16 1.24 1.40 1.13 1.14 .81 .49
Camk2d
KLA  ATP  ATP+KLA
 AK032524 adult male olfactory brain cDNA, RIKEN full-length enriched library, clone:6430579P05 product:calcium/calmodulin-dependent protein kinase II, delta, full insert sequence. [AK032524] KLA 1.31 1.45 1.42 1.21 1.34 1.18 1.16
ATP 1.04 1.29 1.39 1.24 .94 .91 1.22
KLA/ATP 1.46 1.64 1.42 1.24 1.00 .93 1.10
Camk2d
KLA  ATP  ATP+KLA
 NM_001025439 calcium/calmodulin-dependent protein kinase II, delta (Camk2d), transcript variant 1, mRNA [NM_001025439] KLA 1.76 1.75 1.72 1.89 1.47 1.55 1.24
ATP 1.06 1.06 .93 1.01 1.22 .98 2.28
KLA/ATP 1.84 1.78 1.40 1.57 1.07 .60 1.97
Camk2g
KLA  ATP  ATP+KLA
 NM_178597 calcium/calmodulin-dependent protein kinase II gamma (Camk2g), transcript variant 1, mRNA [NM_178597] KLA .23 .24 .23 .44 .70 .73 .70
ATP .91 .85 1.07 .86 .58 .59 .95
KLA/ATP .22 .20 .35 .25 .54 .59 .71
Casp3
KLA  ATP  ATP+KLA
 NM_009810 caspase 3 (Casp3), mRNA [NM_009810] KLA 1.66 1.94 2.47 2.61 3.01 2.96 1.44
ATP .90 .99 1.17 1.30 1.01 1.17 .86
KLA/ATP 1.55 1.87 2.40 2.35 2.27 2.84 2.52
Casp3
KLA  ATP  ATP+KLA
 U49929 ICE-like cysteine protease (Lice) mRNA, complete cds. [U49929] KLA 1.71 1.87 2.69 3.11 3.64 3.42 1.52
ATP 1.04 1.07 1.16 1.34 .98 1.27 .86
KLA/ATP 1.80 1.96 2.46 2.91 2.50 3.24 3.10
Cav1
KLA  ATP  ATP+KLA
 NM_007616 caveolin, caveolae protein 1 (Cav1), mRNA [NM_007616] KLA 14.41 13.85 11.14 10.72 9.47 4.26 1.52
ATP 1.05 1.13 1.37 1.72 3.27 15.82 13.01
KLA/ATP 12.62 15.59 16.15 16.68 11.37 8.19 14.27
Cav2
KLA  ATP  ATP+KLA
 NM_016900 caveolin 2 (Cav2), mRNA [NM_016900] KLA 1.04 1.01 .95 .81 .55 .29 .40
ATP 1.08 1.17 1.18 1.18 1.02 .93 .74
KLA/ATP 1.04 1.08 .96 1.13 .62 .28 .57
Cav3
KLA  ATP  ATP+KLA
 NM_007617 caveolin 3 (Cav3), mRNA [NM_007617] KLA 1.01 1.05 1.01 1.08 .97 1.04 1.07
ATP 1.00 1.00 1.03 1.08 1.02 1.08 .98
KLA/ATP 1.05 .98 .83 1.14 1.09 1.10 1.00
Cbl
KLA  ATP  ATP+KLA
 NM_007619 Casitas B-lineage lymphoma (Cbl), mRNA [NM_007619] KLA 1.23 1.22 1.54 1.84 2.25 2.58 2.75
ATP 1.04 1.12 1.07 1.53 1.55 2.12 3.23
KLA/ATP 1.23 1.20 1.22 1.44 1.31 1.88 6.28
Cblb
KLA  ATP  ATP+KLA
 AK045005 9.5 days embryo parthenogenote cDNA, RIKEN full-length enriched library, clone:B130018P07 product:hypothetical protein, full insert sequence. [AK045005] KLA 1.16 1.11 1.15 1.10 1.16 .98 .93
ATP 1.16 1.23 .98 1.28 1.34 .73 1.55
KLA/ATP 1.26 1.60 1.64 1.23 1.01 .91 1.05
Cblb
KLA  ATP  ATP+KLA
 AK084162 12 days embryo eyeball cDNA, RIKEN full-length enriched library, clone:D230004I05 product:unclassifiable, full insert sequence. [AK084162] KLA .97 .98 1.02 1.01 .84 1.02 1.03
ATP 1.03 1.02 .98 1.09 1.05 .96 .96
KLA/ATP 1.07 .95 .91 .98 .98 1.01 1.00
Cblc
KLA  ATP  ATP+KLA
 NM_023224 Casitas B-lineage lymphoma c (Cblc), mRNA [NM_023224] KLA 1.02 .98 1.01 1.02 1.00 .99 1.05
ATP .94 .95 .97 1.04 .99 .97 .99
KLA/ATP 1.00 1.01 .96 .97 .94 .92 .99
Ccnd1
KLA  ATP  ATP+KLA
 S78355 gb|Cyl-1=cyclin D1 [mice, BALB/c, brain, mRNA, 3737 nt]. [S78355] KLA .24 .23 .23 .24 .29 .47 .17
ATP 1.02 1.02 .88 .80 .52 .10 .21
KLA/ATP .27 .23 .22 .24 .27 .25 .14
Cd44
KLA  ATP  ATP+KLA
 NM_009851 CD44 antigen (Cd44), transcript variant 1, mRNA [NM_009851] KLA 1.87 1.86 1.79 1.42 .99 .54 .67
ATP 1.05 1.16 1.24 1.67 1.79 1.37 .85
KLA/ATP 2.00 2.08 1.53 1.86 1.24 .89 .71
Cd63
KLA  ATP  ATP+KLA
 NM_001042580 Cd63 antigen (Cd63), transcript variant 1, mRNA [NM_001042580] KLA .98 .93 .83 .90 .79 .84 .87
ATP .92 .97 .95 .93 1.09 1.30 1.52
KLA/ATP .84 .94 .98 .84 1.20 1.23 1.27
Cdc42
KLA  ATP  ATP+KLA
 NM_009861 cell division cycle 42 homolog (S. cerevisiae) (Cdc42), mRNA [NM_009861] KLA 1.04 1.01 1.02 1.04 1.12 1.21 1.12
ATP 1.07 1.10 1.04 1.06 1.02 .95 1.14
KLA/ATP .94 1.04 1.01 .97 .95 1.02 1.25
Cdkn1a
KLA  ATP  ATP+KLA
 NM_007669 cyclin-dependent kinase inhibitor 1A (P21) (Cdkn1a), transcript variant 1, mRNA [NM_007669] KLA 4.72 4.90 4.96 3.73 2.11 1.14 1.02
ATP 1.14 1.52 .95 1.69 1.47 2.21 .50
KLA/ATP 5.99 7.08 3.86 6.37 3.00 2.55 2.05
Col1a1
KLA  ATP  ATP+KLA
 NM_007742 collagen, type I, alpha 1 (Col1a1), mRNA [NM_007742] KLA 1.13 1.10 1.22 1.18 1.04 1.15 1.09
ATP 1.03 1.00 1.34 1.48 1.11 1.13 1.11
KLA/ATP 1.13 1.29 1.47 1.77 1.38 1.33 1.13
Col1a2
KLA  ATP  ATP+KLA
 AK031577 13 days embryo male testis cDNA, RIKEN full-length enriched library, clone:6030456A07 product:procollagen, type I, alpha 2, full insert sequence. [AK031577] KLA .98 1.03 1.02 1.01 1.03 1.01 .90
ATP .97 .96 .96 1.00 .92 1.00 1.00
KLA/ATP .97 1.00 1.02 1.06 .96 .98 1.00
Col1a2
KLA  ATP  ATP+KLA
 NM_007743 collagen, type I, alpha 2 (Col1a2), mRNA [NM_007743] KLA 1.25 1.20 1.58 1.41 1.32 1.51 1.08
ATP .92 .97 1.50 1.66 1.38 1.23 1.14
KLA/ATP 1.35 1.46 2.19 2.47 1.99 1.64 1.36
Ctnnb1
KLA  ATP  ATP+KLA
 AK020013 adult male thymus cDNA, RIKEN full-length enriched library, clone:5830416C23 product:catenin beta, full insert sequence. [AK020013] KLA 1.06 1.15 1.00 1.06 1.27 1.14 1.03
ATP .85 .57 1.74 3.36 4.13 2.19 1.55
KLA/ATP 1.12 .87 2.47 3.61 3.79 2.21 2.06
Ctnnb1
KLA  ATP  ATP+KLA
 NM_007614 catenin (cadherin associated protein), beta 1 (Ctnnb1), mRNA [NM_007614] KLA 1.02 1.07 1.13 1.03 1.04 .93 .96
ATP 1.12 1.14 .75 .77 .73 .72 1.52
KLA/ATP 1.18 1.17 .77 .85 .60 .59 1.35
Ctsl
KLA  ATP  ATP+KLA
 NM_009984 cathepsin L (Ctsl), mRNA [NM_009984] KLA .85 .79 .72 .80 .79 .84 .75
ATP 1.02 1.01 1.16 .87 1.73 3.14 6.44
KLA/ATP .72 .80 1.12 .89 1.20 2.53 3.79
Cttn
KLA  ATP  ATP+KLA
 NM_007803 cortactin (Cttn), mRNA [NM_007803] KLA 1.12 1.14 1.28 1.32 1.64 2.25 2.00
ATP 1.04 1.02 .98 1.03 1.02 1.21 1.50
KLA/ATP 1.14 1.20 1.09 1.19 1.15 1.54 2.16
Dcn
KLA  ATP  ATP+KLA
 AK052759 0 day neonate kidney cDNA, RIKEN full-length enriched library, clone:D630044L13 product:unclassifiable, full insert sequence. [AK052759] KLA 1.02 1.03 1.01 .96 .94 1.04 1.03
ATP .97 1.02 1.05 .96 .93 .99 1.01
KLA/ATP 1.03 1.01 1.00 1.02 .97 1.01 1.04
Dcn
KLA  ATP  ATP+KLA
 NM_007833 decorin (Dcn), mRNA [NM_007833] KLA 1.21 1.36 1.45 1.54 1.74 2.09 2.92
ATP 1.01 .98 1.09 1.22 1.20 1.70 2.43
KLA/ATP 1.19 1.34 1.60 1.75 1.99 3.41 18.56
Ddx5
KLA  ATP  ATP+KLA
 NM_007840 DEAD (Asp-Glu-Ala-Asp) box polypeptide 5 (Ddx5), mRNA [NM_007840] KLA 1.36 1.40 1.22 1.23 1.04 1.00 .90
ATP .94 .83 .80 .72 1.35 1.36 .84
KLA/ATP 1.30 1.19 1.09 .94 2.47 1.47 .81
Egfr
KLA  ATP  ATP+KLA
 NM_007912 epidermal growth factor receptor (Egfr), transcript variant 2, mRNA [NM_007912] KLA 1.10 1.07 1.14 1.11 1.08 1.03 .90
ATP .99 1.00 1.04 .98 .97 1.15 1.14
KLA/ATP 1.07 1.10 1.16 1.08 1.01 .97 .94
Egfr
KLA  ATP  ATP+KLA
 NM_207655 epidermal growth factor receptor (Egfr), transcript variant 1, mRNA [NM_207655] KLA 1.57 1.44 1.47 1.31 .96 .92 .76
ATP .97 .93 1.10 1.00 1.41 2.97 .86
KLA/ATP 1.44 1.50 1.61 1.30 1.14 1.21 .82
Eif4b
KLA  ATP  ATP+KLA
 NM_145625 eukaryotic translation initiation factor 4B (Eif4b), mRNA [NM_145625] KLA .93 .95 .95 .80 .75 .73 .97
ATP 1.08 1.19 1.04 1.43 1.34 1.48 1.04
KLA/ATP 1.13 1.07 .93 1.10 .98 1.19 1.55
Elk1
KLA  ATP  ATP+KLA
 AK082260 0 day neonate cerebellum cDNA, RIKEN full-length enriched library, clone:C230030F12 product:ELK1, member of ETS oncogene family, full insert sequence. [AK082260] KLA 1.02 1.01 1.01 .97 1.00 1.03 1.06
ATP 1.02 1.07 1.06 1.03 1.02 1.02 1.00
KLA/ATP 1.08 .99 .97 1.01 1.02 1.06 .95
Erbb2
KLA  ATP  ATP+KLA
 NM_001003817 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) (Erbb2), mRNA [NM_001003817] KLA 1.01 1.00 .98 1.01 .98 .99 .97
ATP .99 1.00 1.00 1.00 .96 .98 .99
KLA/ATP 1.00 1.01 1.01 1.02 .96 .98 .97
Erbb3
KLA  ATP  ATP+KLA
 BC049279 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian), mRNA (cDNA clone IMAGE:4460595), partial cds. [BC049279] KLA .71 .74 .77 .92 1.26 1.39 1.01
ATP .92 .90 .92 .70 .43 .93 1.08
KLA/ATP .66 .70 .71 .61 .56 1.15 1.29
Erbb3
KLA  ATP  ATP+KLA
 NM_010153 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian) (Erbb3), mRNA [NM_010153] KLA .98 .99 .98 .98 .98 1.03 1.01
ATP 1.01 1.00 .95 1.00 .94 .95 1.01
KLA/ATP .98 1.03 .95 .99 .99 .99 .93
Erbb4
KLA  ATP  ATP+KLA
 NM_010154 v-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian) (Erbb4), mRNA [NM_010154] KLA 1.06 .98 .93 .99 1.02 .98 .91
ATP 1.01 .97 .93 .96 1.00 1.01 1.01
KLA/ATP .94 .96 1.03 .99 .87 .95 1.02
Esr1
KLA  ATP  ATP+KLA
 NM_007956 estrogen receptor 1 (alpha) (Esr1), mRNA [NM_007956] KLA 1.06 1.05 1.11 1.36 1.33 1.02 .90
ATP 1.05 .92 1.02 .94 1.02 .83 .67
KLA/ATP 1.02 .98 1.09 1.08 1.32 1.07 .71
Ezr
KLA  ATP  ATP+KLA
 NM_009510 ezrin (Ezr), mRNA [NM_009510] KLA 2.87 2.71 2.24 2.32 2.31 1.91 1.08
ATP 1.04 1.05 1.11 1.87 4.65 5.96 1.64
KLA/ATP 2.94 2.63 2.59 3.03 2.98 3.38 4.32
Fas
KLA  ATP  ATP+KLA
 AK086933 0 day neonate lung cDNA, RIKEN full-length enriched library, clone:E030012O08 product:tumor necrosis factor receptor superfamily, member 6, full insert sequence. [AK086933] KLA 6.31 6.56 6.33 6.70 4.93 3.74 2.48
ATP .95 1.04 1.33 1.55 1.85 6.00 2.77
KLA/ATP 5.67 7.16 7.71 7.73 6.02 5.79 7.85
Fas
KLA  ATP  ATP+KLA
 NM_007987 Fas (TNF receptor superfamily member 6) (Fas), mRNA [NM_007987] KLA 17.08 17.45 19.08 17.38 13.33 6.78 4.46
ATP .98 .96 1.64 3.05 5.58 12.91 1.89
KLA/ATP 16.57 17.25 26.06 23.57 22.03 16.74 13.29
Fasl
KLA  ATP  ATP+KLA
 NM_010177 Fas ligand (TNF superfamily, member 6) (Fasl), mRNA [NM_010177] KLA 1.03 1.01 1.03 1.02 1.01 1.01 1.00
ATP 1.00 .99 1.04 1.21 1.18 1.20 1.01
KLA/ATP 1.00 1.02 1.07 1.16 1.18 1.23 1.00
Fgf1
KLA  ATP  ATP+KLA
 NM_010197 fibroblast growth factor 1 (Fgf1), mRNA [NM_010197] KLA 1.07 .99 .99 1.00 1.03 .97 .99
ATP 1.01 1.03 1.01 .95 .95 .98 .88
KLA/ATP 1.03 .99 .97 .99 .98 .94 1.01
Fgf10
KLA  ATP  ATP+KLA
 NM_008002 fibroblast growth factor 10 (Fgf10), mRNA [NM_008002] KLA .99 .98 1.02 1.00 1.02 1.02 1.02
ATP 1.03 1.02 1.00 1.00 1.00 .99 .99
KLA/ATP 1.01 1.00 1.04 .99 1.00 1.02 1.01
Fgf11
KLA  ATP  ATP+KLA
 BC066859 fibroblast growth factor 11, mRNA (cDNA clone MGC:76712 IMAGE:30101881), complete cds [BC066859] KLA .64 .61 .55 .58 .51 .48 .77
ATP 1.00 .96 .78 .78 .63 .44 .48
KLA/ATP .64 .63 .59 .56 .54 .42 .40
Fgf11
KLA  ATP  ATP+KLA
 NM_010198 fibroblast growth factor 11 (Fgf11), mRNA [NM_010198] KLA .99 1.02 1.05 1.04 1.01 1.03 1.07
ATP .95 1.02 1.02 1.07 .98 1.01 1.07
KLA/ATP 1.01 1.01 1.08 .96 .97 .95 1.01
Fgf12
KLA  ATP  ATP+KLA
 NM_183064 fibroblast growth factor 12 (Fgf12), transcript variant 1, mRNA [NM_183064] KLA .96 .97 1.05 .99 .97 1.01 1.01
ATP .93 .97 .97 .97 .99 .95 1.00
KLA/ATP 1.02 1.05 1.10 1.02 .95 1.01 .95
Fgf13
KLA  ATP  ATP+KLA
 NM_010200 fibroblast growth factor 13 (Fgf13), mRNA [NM_010200] KLA .91 .92 .93 .84 .77 .66 .75
ATP 1.09 1.14 1.03 1.11 1.06 .68 .78
KLA/ATP .98 1.02 .86 .90 .78 .70 .79
Fgf14
KLA  ATP  ATP+KLA
 NM_010201 fibroblast growth factor 14 (Fgf14), transcript variant 1, mRNA [NM_010201] KLA 1.04 1.05 1.02 1.04 1.03 1.05 1.03
ATP .99 1.08 1.04 1.00 .99 .98 1.04
KLA/ATP 1.00 1.00 1.08 1.00 1.04 1.01 1.03
Fgf14
KLA  ATP  ATP+KLA
 NM_207667 fibroblast growth factor 14 (Fgf14), transcript variant 2, mRNA [NM_207667] KLA 1.04 1.01 .98 .93 .96 .96 .97
ATP 1.04 1.10 .94 .87 1.03 .99 .96
KLA/ATP .86 .94 1.03 .89 1.00 .90 1.03
Fgf15
KLA  ATP  ATP+KLA
 NM_008003 fibroblast growth factor 15 (Fgf15), mRNA [NM_008003] KLA 1.00 1.00 .95 .98 .92 .96 1.01
ATP .99 1.01 .98 .98 .93 .95 .97
KLA/ATP .98 1.01 1.02 1.03 .97 .97 1.00
Fgf16
KLA  ATP  ATP+KLA
 NM_030614 fibroblast growth factor 16 (Fgf16), mRNA [NM_030614] KLA 1.00 .97 .99 1.02 1.04 .97 .97
ATP 1.02 .99 .99 1.02 1.12 1.01 1.02
KLA/ATP 1.06 1.02 .99 1.01 1.00 1.10 1.03
Fgf17
KLA  ATP  ATP+KLA
 NM_008004 fibroblast growth factor 17 (Fgf17), mRNA [NM_008004] KLA .97 1.03 .98 1.00 .97 .97 .86
ATP .99 .96 .99 .90 1.02 1.01 1.01
KLA/ATP .99 .91 1.08 .99 .99 .98 .99
Fgf18
KLA  ATP  ATP+KLA
 NM_008005 fibroblast growth factor 18 (Fgf18), mRNA [NM_008005] KLA 1.17 1.18 1.16 1.12 1.03 1.13 1.04
ATP .96 .98 2.47 12.57 2.76 1.56 1.03
KLA/ATP 1.01 1.15 2.33 10.13 2.80 1.79 1.02
Fgf2
KLA  ATP  ATP+KLA
 NM_008006 fibroblast growth factor 2 (Fgf2), mRNA [NM_008006] KLA 1.02 1.01 1.00 1.03 1.01 1.02 1.01
ATP .99 1.01 1.00 1.02 1.01 1.01 1.00
KLA/ATP 1.00 1.01 .98 1.01 1.02 1.03 1.01
Fgf20
KLA  ATP  ATP+KLA
 NM_030610 fibroblast growth factor 20 (Fgf20), mRNA [NM_030610] KLA .97 1.08 .99 1.00 .97 1.00 .97
ATP 1.03 .95 .97 1.05 .98 .97 1.00
KLA/ATP .99 .99 1.06 1.04 1.02 .92 .96
Fgf21
KLA  ATP  ATP+KLA
 NM_020013 fibroblast growth factor 21 (Fgf21), mRNA [NM_020013] KLA 1.02 1.03 .87 1.04 1.00 1.01 1.00
ATP 1.04 .97 1.00 1.02 .96 1.05 1.02
KLA/ATP 1.08 1.00 1.00 1.00 1.03 1.02 .99
Fgf22
KLA  ATP  ATP+KLA
 AK008922 adult male stomach cDNA, RIKEN full-length enriched library, clone:2210414E06 product:FIBROBLAST GROWTH FACTOR-22 PRECURSOR (FGF-22) homolog [Mus musculus], full insert sequence [AK008922] KLA .90 .94 .95 1.04 1.03 .94 .97
ATP 1.04 1.01 .98 .93 .93 .95 .88
KLA/ATP .98 .97 .97 1.01 .95 .92 .95
Fgf22
KLA  ATP  ATP+KLA
 NM_023304 fibroblast growth factor 22 (Fgf22), mRNA [NM_023304] KLA .99 .94 1.01 .95 .97 .89 .99
ATP 1.00 .95 1.00 .96 .97 .93 .98
KLA/ATP .91 1.00 1.01 .92 .95 .98 .97
Fgf23
KLA  ATP  ATP+KLA
 NM_022657 fibroblast growth factor 23 (Fgf23), mRNA [NM_022657] KLA 1.32 1.39 1.27 1.22 1.07 1.03 1.14
ATP .95 1.00 1.05 1.07 1.05 1.02 .96
KLA/ATP 1.32 1.39 1.37 1.22 1.01 1.00 .90
Fgf3
KLA  ATP  ATP+KLA
 NM_008007 fibroblast growth factor 3 (Fgf3), mRNA [NM_008007] KLA 1.03 1.05 1.00 .97 1.01 .98 .97
ATP 1.01 1.00 .97 1.03 .98 1.03 .97
KLA/ATP .98 1.00 1.01 1.03 1.03 1.00 .99
Fgf5
KLA  ATP  ATP+KLA
 NM_010203 fibroblast growth factor 5 (Fgf5), mRNA [NM_010203] KLA 1.02 1.02 1.00 1.03 .97 1.05 .99
ATP 1.02 1.00 1.03 .97 .99 .97 1.04
KLA/ATP 1.05 .92 1.01 1.00 1.11 .96 .97
Fgf6
KLA  ATP  ATP+KLA
 M92416 fibroblast growth factor (Fgf6) mRNA, 3 end [M92416] KLA 1.09 1.07 1.00 1.06 .97 1.01 .96
ATP 1.02 1.02 1.06 1.02 .93 .99 .98
KLA/ATP 1.04 .99 1.00 .99 1.00 1.00 1.03
Fgf6
KLA  ATP  ATP+KLA
 NM_010204 fibroblast growth factor 6 (Fgf6), mRNA [NM_010204] KLA 1.00 .96 1.06 .96 .96 1.00 .91
ATP .94 1.00 .89 .95 1.01 .92 1.00
KLA/ATP .99 1.06 1.06 .86 1.00 .95 1.00
Fgf7
KLA  ATP  ATP+KLA
 NM_008008 fibroblast growth factor 7 (Fgf7), mRNA [NM_008008] KLA 1.02 1.02 1.02 1.03 1.05 1.11 1.04
ATP 1.00 1.01 1.11 1.15 1.05 1.04 1.06
KLA/ATP .99 .96 .83 1.10 1.15 1.26 1.21
Fgf8
KLA  ATP  ATP+KLA
 BC048734 fibroblast growth factor 8, mRNA (cDNA clone MGC:59627 IMAGE:6513131), complete cds [BC048734] KLA .96 .95 1.03 .96 1.06 .97 .96
ATP 1.08 .94 1.07 1.10 1.00 .93 1.06
KLA/ATP 1.03 1.02 1.04 .96 1.04 .94 .94
Fgf8
KLA  ATP  ATP+KLA
 NM_010205 fibroblast growth factor 8 (Fgf8), mRNA [NM_010205] KLA 1.00 1.00 1.03 1.04 1.04 1.07 1.09
ATP 1.01 1.01 1.11 1.14 1.11 1.09 1.05
KLA/ATP 1.00 1.04 1.14 1.18 1.15 1.09 1.04
Fgf9
KLA  ATP  ATP+KLA
 NM_013518 fibroblast growth factor 9 (Fgf9), mRNA [NM_013518] KLA 1.04 1.07 1.07 1.12 .97 .96 .91
ATP 1.02 1.08 .98 1.00 .94 .99 .92
KLA/ATP 1.04 1.03 1.03 1.00 .93 .93 .89
Fgfr1
KLA  ATP  ATP+KLA
 M28998 gb|Mouse basic fibroblast growth factor receptor (bFGF-R) mRNA, complete cds. [M28998] KLA .82 .79 .73 .66 .50 .55 .65
ATP 1.01 1.08 .86 .90 1.29 1.24 1.52
KLA/ATP .85 .82 .71 .71 .63 .80 .85
Fgfr1
KLA  ATP  ATP+KLA
 NM_010206 fibroblast growth factor receptor 1 (Fgfr1), transcript variant 1, mRNA [NM_010206] KLA .92 .86 .73 .82 .79 .85 .84
ATP 1.01 1.06 .92 .92 1.18 1.02 1.22
KLA/ATP .83 .83 .79 .76 .83 .83 .92
Flna
KLA  ATP  ATP+KLA
 AK044856 9.5 days embryo parthenogenote cDNA, RIKEN full-length enriched library, clone:B130008E07 product:hypothetical Calponin homology (CH) domain containing protein, full insert sequence. [AK044856] KLA .95 .95 1.00 .99 1.02 1.10 1.00
ATP .93 .94 1.02 1.08 1.04 1.01 .99
KLA/ATP 1.02 .98 .99 .98 1.02 1.08 1.02
Flna
KLA  ATP  ATP+KLA
 NM_010227 filamin, alpha (Flna), mRNA [NM_010227] KLA .90 .91 .92 .83 1.03 1.12 .82
ATP 1.02 1.06 .77 .69 .58 .69 .72
KLA/ATP .97 .90 .69 .66 .49 .59 .83
Flnb
KLA  ATP  ATP+KLA
 AK050046 adult male liver tumor cDNA, RIKEN full-length enriched library, clone:C730006K15 product:filamin, beta, full insert sequence. [AK050046] KLA 5.58 4.67 5.09 3.71 3.12 1.55 1.22
ATP .97 1.04 1.40 1.56 2.09 1.87 1.06
KLA/ATP 6.20 5.77 5.48 4.31 2.53 2.35 1.37
Flnb
KLA  ATP  ATP+KLA
 NM_134080 filamin, beta (Flnb), mRNA [NM_134080] KLA 8.86 8.95 10.89 9.75 10.94 7.28 1.54
ATP 1.03 1.08 1.17 1.39 1.82 2.72 1.01
KLA/ATP 8.89 10.37 11.36 10.83 7.90 5.59 3.36
Flnc
KLA  ATP  ATP+KLA
 AK051985 12 days embryo eyeball cDNA, RIKEN full-length enriched library, clone:D230030L22 product:weakly similar to CGABP260 ACTIN-BINDING DOMAIN (FRAGMENT) [Gallus gallus], full insert sequence. [AK051985] KLA .97 1.04 1.01 1.03 1.01 1.05 1.06
ATP 1.02 1.04 1.00 1.02 1.02 1.10 1.06
KLA/ATP 1.00 1.00 .98 1.07 1.03 1.07 1.04
Flnc
KLA  ATP  ATP+KLA
 NM_001081185 filamin C, gamma (actin binding protein 280) (Flnc), mRNA [NM_001081185] KLA .95 1.00 1.02 1.00 .95 .98 1.05
ATP 1.02 1.01 1.11 1.37 1.04 1.04 1.13
KLA/ATP .99 1.02 .93 1.00 .90 .99 1.03
Fn1
KLA  ATP  ATP+KLA
 NM_010233 fibronectin 1 (Fn1), mRNA [NM_010233] KLA 1.23 1.30 1.38 1.12 1.16 1.00 .78
ATP 1.02 1.19 1.25 1.56 1.33 1.05 .95
KLA/ATP 1.36 1.51 1.34 1.70 1.20 1.06 .93
Frap1
KLA  ATP  ATP+KLA
 NM_020009 FK506 binding protein 12-rapamycin associated protein 1 (Frap1), mRNA [NM_020009] KLA 1.37 1.32 1.46 1.57 1.83 1.29 1.28
ATP 1.12 1.07 .95 .91 .80 .77 1.03
KLA/ATP 1.45 1.51 1.50 1.11 .89 .87 1.01
Frs2
KLA  ATP  ATP+KLA
 NM_177798 fibroblast growth factor receptor substrate 2 (Frs2), mRNA [NM_177798] KLA 1.54 1.42 1.33 1.36 1.22 1.43 1.09
ATP .97 .98 1.08 .70 1.76 1.90 1.17
KLA/ATP 1.46 1.35 1.38 .89 1.97 2.48 1.79
Fzd1
KLA  ATP  ATP+KLA
 NM_021457 frizzled homolog 1 (Drosophila) (Fzd1), mRNA [NM_021457] KLA 15.53 16.47 14.36 11.40 6.80 2.73 2.49
ATP 1.01 1.02 1.39 2.05 6.43 10.47 1.41
KLA/ATP 12.71 14.30 14.99 14.06 9.72 9.90 8.10
Fzd10
KLA  ATP  ATP+KLA
 NM_175284 frizzled homolog 10 (Drosophila) (Fzd10), mRNA [NM_175284] KLA .99 .98 .99 1.03 1.03 1.02 .99
ATP .98 .98 .97 1.03 1.05 1.00 .96
KLA/ATP .96 .98 1.08 1.02 1.04 1.02 1.00
Fzd2
KLA  ATP  ATP+KLA
 NM_020510 frizzled homolog 2 (Drosophila) (Fzd2), mRNA [NM_020510] KLA .97 1.01 1.01 1.02 1.00 .96 .97
ATP 1.01 1.02 1.03 1.02 .97 1.03 .93
KLA/ATP 1.04 .98 .99 1.03 .99 1.03 .98
Fzd3
KLA  ATP  ATP+KLA
 NM_021458 frizzled homolog 3 (Drosophila) (Fzd3), mRNA [NM_021458] KLA 1.00 1.00 .99 1.04 1.02 1.06 1.07
ATP 1.00 1.00 .95 1.04 1.04 1.01 1.05
KLA/ATP .98 1.05 1.06 .99 1.02 1.00 1.03
Fzd4
KLA  ATP  ATP+KLA
 NM_008055 frizzled homolog 4 (Drosophila) (Fzd4), mRNA [NM_008055] KLA .96 .88 .91 .92 .82 .89 .84
ATP .97 .98 1.05 1.02 .93 .90 .96
KLA/ATP .82 .86 .97 .92 .88 .91 .92
Fzd5
KLA  ATP  ATP+KLA
 NM_022721 frizzled homolog 5 (Drosophila) (Fzd5), transcript variant 1, mRNA [NM_022721] KLA 1.63 1.69 1.56 1.23 .91 1.01 .92
ATP 1.03 1.32 4.46 9.23 7.72 2.14 1.11
KLA/ATP 1.63 1.92 4.20 8.67 8.29 3.07 1.12
Fzd6
KLA  ATP  ATP+KLA
 NM_008056 frizzled homolog 6 (Drosophila) (Fzd6), mRNA [NM_008056] KLA .97 1.01 .96 .90 .87 .94 .98
ATP .98 .97 .98 .94 .95 1.09 .96
KLA/ATP .97 1.02 .94 .92 .90 1.02 1.00
Fzd7
KLA  ATP  ATP+KLA
 NM_008057 frizzled homolog 7 (Drosophila) (Fzd7), mRNA [NM_008057] KLA 1.50 1.68 1.53 1.31 1.13 1.00 .94
ATP 1.04 1.12 1.60 3.45 2.56 1.72 1.02
KLA/ATP 1.89 1.92 1.96 4.61 3.75 3.38 1.88
Fzd8
KLA  ATP  ATP+KLA
 AK034561 12 days embryo embryonic body between diaphragm region and neck cDNA, RIKEN full-length enriched library, clone:9430006K02 product:inferred: transmembrane receptor {Mus musculus}; frizzled homolog 8 (Drosophila) homolog {GNF expression}, KLA 1.00 .98 1.05 .98 .96 1.03 .94
ATP 1.00 .92 1.06 1.05 1.02 1.01 .98
KLA/ATP .99 1.06 .99 .94 .95 .99 1.03
Fzd8
KLA  ATP  ATP+KLA
 NM_008058 frizzled homolog 8 (Drosophila) (Fzd8), mRNA [NM_008058] KLA 1.09 1.15 1.07 1.05 1.03 1.05 .98
ATP 1.05 1.08 2.01 3.38 2.89 1.20 1.03
KLA/ATP 1.04 1.17 1.65 2.57 2.62 1.40 1.04
Fzd9
KLA  ATP  ATP+KLA
 NM_010246 frizzled homolog 9 (Drosophila) (Fzd9), mRNA [NM_010246] KLA 1.03 1.10 1.12 .96 .98 1.00 .94
ATP 1.00 1.00 1.03 1.06 1.07 1.14 .98
KLA/ATP 1.10 1.07 1.03 .84 1.11 .96 .98
Gab1
KLA  ATP  ATP+KLA
 NM_021356 growth factor receptor bound protein 2-associated protein 1 (Gab1), mRNA [NM_021356] KLA .83 .95 1.12 1.59 3.13 3.14 1.50
ATP .94 .96 1.12 1.74 2.35 5.20 1.66
KLA/ATP .79 .78 1.32 3.74 3.08 4.44 2.62
Gpc1
KLA  ATP  ATP+KLA
 NM_016696 glypican 1 (Gpc1), mRNA [NM_016696] KLA 3.01 3.08 2.73 3.25 3.51 2.69 1.00
ATP 1.00 1.09 1.22 1.42 2.55 5.92 8.10
KLA/ATP 2.59 3.47 3.36 3.88 4.94 5.79 6.79
Gpc3
KLA  ATP  ATP+KLA
 NM_016697 glypican 3 (Gpc3), mRNA [NM_016697] KLA .99 .94 .92 .97 1.08 1.00 .96
ATP 1.00 .97 1.02 1.02 1.05 .98 .99
KLA/ATP .97 .97 .97 1.03 1.00 .98 .97
Grb2
KLA  ATP  ATP+KLA
 NM_008163 growth factor receptor bound protein 2 (Grb2), mRNA [NM_008163] KLA .92 .88 .90 1.27 1.43 1.22 1.00
ATP 1.02 .83 .51 .42 .92 .70 .57
KLA/ATP .84 .77 .61 .56 1.56 1.49 .52
Grb2
KLA  ATP  ATP+KLA
 U07617 Grb2 adaptor protein (grb2) mRNA, complete cds. [U07617] KLA .83 .80 .95 1.13 1.38 1.36 1.06
ATP .84 .74 .51 .41 .82 .74 .59
KLA/ATP .77 .70 .57 .54 1.49 1.39 .53
Hbegf
KLA  ATP  ATP+KLA
 NM_010415 heparin-binding EGF-like growth factor (Hbegf), mRNA [NM_010415] KLA 4.85 5.22 4.43 2.64 1.67 1.05 .85
ATP 1.16 1.29 9.30 21.54 19.63 14.93 4.45
KLA/ATP 5.32 5.51 13.94 26.41 22.89 13.95 5.50
Hcls1
KLA  ATP  ATP+KLA
 NM_008225 hematopoietic cell specific Lyn substrate 1 (Hcls1), mRNA [NM_008225] KLA 1.40 1.40 1.33 1.57 2.01 2.26 2.51
ATP 1.12 1.08 .92 .87 .83 1.27 1.81
KLA/ATP 1.31 1.48 1.39 1.35 1.05 1.17 3.13
Hgf
KLA  ATP  ATP+KLA
 AK033274 15 days embryo male testis cDNA, RIKEN full-length enriched library, clone:8030481P22 product:inferred: hepatocyte growth factor [AK033274] KLA 1.34 1.22 .96 .93 .82 .93 .87
ATP 1.64 2.45 3.30 1.89 .97 1.12 .90
KLA/ATP 1.49 2.50 3.96 1.88 1.07 1.00 .83
Hgf
KLA  ATP  ATP+KLA
 NM_010427 hepatocyte growth factor (Hgf), mRNA [NM_010427] KLA 1.11 1.18 1.30 1.20 1.08 .96 1.14
ATP 1.02 1.14 1.32 1.62 1.17 1.26 1.47
KLA/ATP 1.18 1.24 1.33 1.84 1.19 1.09 1.31
Hif1a
KLA  ATP  ATP+KLA
 NM_010431 hypoxia inducible factor 1, alpha subunit (Hif1a), mRNA [NM_010431] KLA 2.52 2.50 2.52 1.78 1.87 1.39 1.96
ATP 1.16 1.37 1.11 1.44 2.11 4.46 1.97
KLA/ATP 2.76 2.92 1.75 2.60 2.39 4.75 5.37
Hoxa10
KLA  ATP  ATP+KLA
 NM_008263 homeo box A10 (Hoxa10), transcript variant 1, mRNA [NM_008263] KLA 1.04 1.04 1.05 1.02 .99 .94 .99
ATP .95 .95 .90 .97 .99 1.04 1.03
KLA/ATP .99 .99 .98 1.01 1.05 .97 .95
Hoxc10
KLA  ATP  ATP+KLA
 NM_010462 homeo box C10 (Hoxc10), mRNA [NM_010462] KLA 1.03 .99 1.01 1.02 .99 1.01 .94
ATP 1.02 1.02 1.00 .96 .99 1.07 1.03
KLA/ATP .98 .97 1.02 1.01 .99 .94 1.01
Hoxd10
KLA  ATP  ATP+KLA
 NM_013554 homeo box D10 (Hoxd10), mRNA [NM_013554] KLA .99 1.04 .99 1.14 1.00 1.10 1.18
ATP .96 1.02 1.09 1.00 1.04 .88 .94
KLA/ATP .97 1.00 1.16 .91 1.09 .98 .91
Hpse
KLA  ATP  ATP+KLA
 NM_152803 heparanase (Hpse), mRNA [NM_152803] KLA 1.99 1.93 2.60 2.97 2.72 1.99 1.34
ATP 1.17 1.20 1.06 1.43 1.25 .98 1.30
KLA/ATP 2.23 2.49 2.45 2.70 1.84 2.05 2.71
Hras1
KLA  ATP  ATP+KLA
 NM_008284 Harvey rat sarcoma virus oncogene 1 (Hras1), mRNA [NM_008284] KLA .79 .82 .77 .82 .94 1.03 1.07
ATP 1.01 .95 .69 .83 .79 1.12 1.15
KLA/ATP .84 .77 .61 .65 .82 1.00 1.05
Hspb2
KLA  ATP  ATP+KLA
 NM_024441 heat shock protein 2 (Hspb2), mRNA [NM_024441] KLA 1.01 1.06 .95 1.04 1.01 1.01 .93
ATP .99 1.02 .97 .94 .93 .95 1.01
KLA/ATP .99 1.00 1.04 1.01 .92 .95 1.01
Igf1
KLA  ATP  ATP+KLA
 AK050118 adult male liver tumor cDNA, RIKEN full-length enriched library, clone:C730016P09 product:unclassifiable, full insert sequence. [AK050118] KLA .13 .14 .15 .16 .22 .34 .48
ATP 1.78 2.05 1.37 .72 .34 .41 .58
KLA/ATP .24 .45 .50 .24 .20 .26 .68
Igf1
KLA  ATP  ATP+KLA
 NM_010512 insulin-like growth factor 1 (Igf1), transcript variant 1, mRNA [NM_010512] KLA .84 .78 .76 .67 .54 .48 .59
ATP .97 .98 1.13 1.13 1.03 .88 .89
KLA/ATP .82 .81 .93 .86 .83 .65 .89
Igf1
KLA  ATP  ATP+KLA
 NM_184052 insulin-like growth factor 1 (Igf1), transcript variant 2, mRNA [NM_184052] KLA .77 .82 .76 .65 .60 .52 .69
ATP 1.01 1.07 .98 1.06 1.03 .78 .94
KLA/ATP .89 .86 .77 .80 .75 .65 .89
Igf1r
KLA  ATP  ATP+KLA
 NM_010513 insulin-like growth factor I receptor (Igf1r), mRNA [NM_010513] KLA 1.32 1.32 1.08 .91 .55 .48 .45
ATP 1.03 1.06 1.06 1.29 1.31 1.45 .47
KLA/ATP 1.30 1.37 1.11 1.00 .93 1.02 .45
Igf2
KLA  ATP  ATP+KLA
 NM_010514 insulin-like growth factor 2 (Igf2), transcript variant 1, mRNA [NM_010514] KLA 1.13 1.12 1.13 1.12 1.13 1.06 1.08
ATP .99 .99 1.00 1.02 1.02 1.00 1.04
KLA/ATP 1.13 1.16 1.13 1.15 1.14 1.09 1.12
Il12b
KLA  ATP  ATP+KLA
 NM_008352 interleukin 12b (Il12b), mRNA [NM_008352] KLA 194.79 211.32 198.97 173.01 142.24 40.28 3.10
ATP 1.05 1.10 1.59 1.99 2.71 2.72 1.52
KLA/ATP 191.27 223.23 280.10 224.29 183.03 68.43 10.69
Iqgap1
KLA  ATP  ATP+KLA
 NM_016721 IQ motif containing GTPase activating protein 1 (Iqgap1), mRNA [NM_016721] KLA 1.02 1.12 1.02 .85 .93 .86 .84
ATP 1.08 1.17 .93 1.22 .89 .68 1.00
KLA/ATP 1.17 1.13 .76 1.00 .67 .69 1.08
Itga2
KLA  ATP  ATP+KLA
 NM_008396 integrin alpha 2 (Itga2), mRNA [NM_008396] KLA 1.03 1.00 .98 1.01 .97 .96 1.00
ATP 1.05 .99 .93 1.02 1.04 1.03 .97
KLA/ATP .98 1.06 1.03 1.00 1.00 1.01 1.01
Itga5
KLA  ATP  ATP+KLA
 NM_010577 integrin alpha 5 (fibronectin receptor alpha) (Itga5), mRNA [NM_010577] KLA 2.63 3.04 2.81 2.47 4.61 5.45 4.90
ATP 1.13 1.62 .74 2.21 1.31 1.93 2.84
KLA/ATP 3.55 3.84 1.15 3.03 1.11 2.81 10.42
Itgav
KLA  ATP  ATP+KLA
 AK052514 13 days embryo lung cDNA, RIKEN full-length enriched library, clone:D430040G12 product:hypothetical protein, full insert sequence. [AK052514] KLA 1.04 .93 1.05 1.02 1.01 .93 1.03
ATP 1.05 1.04 1.13 1.12 1.12 .91 1.02
KLA/ATP 1.08 .97 1.02 .95 1.01 .96 1.05
Itgav
KLA  ATP  ATP+KLA
 AK171739 activated spleen cDNA, RIKEN full-length enriched library, clone:F830008B15 product:unclassifiable, full insert sequence. [AK171739] KLA 1.04 .97 1.06 .95 1.15 .89 1.11
ATP 1.41 1.54 1.64 2.24 2.74 1.24 1.18
KLA/ATP 1.09 1.07 1.03 1.01 1.72 1.24 1.10
Itgav
KLA  ATP  ATP+KLA
 NM_008402 integrin alpha V (Itgav), mRNA [NM_008402] KLA 4.00 3.99 3.28 2.24 1.57 .95 1.13
ATP 1.14 1.22 1.13 1.39 2.22 2.47 1.70
KLA/ATP 4.59 4.61 2.48 2.44 1.60 1.88 2.56
Itgb1
KLA  ATP  ATP+KLA
 NM_010578 integrin beta 1 (fibronectin receptor beta) (Itgb1), mRNA [NM_010578] KLA 1.05 1.09 1.13 .92 1.01 .93 .88
ATP 1.14 1.30 .92 1.07 1.04 .83 .70
KLA/ATP 1.26 1.30 .87 1.02 .66 .65 .62
Itgb1
KLA  ATP  ATP+KLA
 U37029 integrin beta1D mRNA, partial cds. [U37029] KLA .93 .95 .96 1.01 .97 1.01 .98
ATP 1.05 .99 .99 1.03 1.03 .97 .94
KLA/ATP .99 .98 1.04 .97 1.02 1.01 .99
Itgb3
KLA  ATP  ATP+KLA
 AF026509 integrin beta3 subunit mRNA, complete cds. [AF026509] KLA 2.38 2.64 2.65 3.15 4.02 4.46 2.83
ATP 1.21 1.17 1.25 1.62 2.33 3.09 4.78
KLA/ATP 2.48 2.63 3.39 3.72 4.30 4.71 6.79
Itgb3
KLA  ATP  ATP+KLA
 NM_016780 integrin beta 3 (Itgb3), mRNA [NM_016780] KLA .50 .51 .52 .41 .31 .25 .15
ATP .94 .88 1.17 .89 .99 1.36 .91
KLA/ATP .51 .54 .67 .52 .61 .74 .48
Itgb5
KLA  ATP  ATP+KLA
 NM_010580 integrin beta 5 (Itgb5), mRNA [NM_010580] KLA .72 .68 .67 .66 .54 .43 .36
ATP 1.09 .94 .78 .57 .63 .56 .62
KLA/ATP .78 .64 .67 .51 .64 .67 .38
Itpr1
KLA  ATP  ATP+KLA
 NM_010585 inositol 1,4,5-triphosphate receptor 1 (Itpr1), mRNA [NM_010585] KLA 3.66 3.69 6.74 8.11 7.08 4.40 1.22
ATP 1.08 .95 1.19 .94 1.09 1.00 .68
KLA/ATP 3.48 3.58 5.86 6.03 4.01 2.31 .97
Itpr2
KLA  ATP  ATP+KLA
 NM_019923 inositol 1,4,5-triphosphate receptor 2 (Itpr2), transcript variant 1, mRNA [NM_019923] KLA 1.41 1.38 1.43 1.42 1.30 1.07 1.01
ATP 1.00 1.00 .97 .97 1.07 1.15 1.06
KLA/ATP 1.39 1.48 1.64 1.42 1.07 .83 .95
Itpr3
KLA  ATP  ATP+KLA
 NM_080553 inositol 1,4,5-triphosphate receptor 3 (Itpr3), mRNA [NM_080553] KLA .55 .51 .45 .41 .34 .34 .45
ATP 1.01 .92 1.02 .57 .46 .34 1.22
KLA/ATP .56 .48 .48 .29 .33 .27 .65
Kdr
KLA  ATP  ATP+KLA
 AK054510 2 days pregnant adult female ovary cDNA, RIKEN full-length enriched library, clone:E330034B14 product:kinase insert domain protein receptor, full insert sequence. [AK054510] KLA 1.00 1.00 .98 1.03 1.02 1.00 .99
ATP .99 1.00 1.00 1.02 1.00 1.00 1.00
KLA/ATP 1.01 1.02 1.03 1.02 .98 1.00 1.01
Kdr
KLA  ATP  ATP+KLA
 NM_010612 kinase insert domain protein receptor (Kdr), mRNA [NM_010612] KLA 7.30 7.28 6.48 6.79 5.97 6.18 2.71
ATP 1.00 .84 1.06 1.14 3.62 3.10 7.15
KLA/ATP 6.62 7.17 7.12 6.48 14.11 12.63 11.01
Kras
KLA  ATP  ATP+KLA
 NM_021284 v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (Kras), mRNA [NM_021284] KLA .53 .49 .40 .42 .49 .95 1.05
ATP .98 1.01 1.16 1.17 1.39 1.29 1.74
KLA/ATP .50 .47 .50 .56 1.00 1.24 1.58
Lum
KLA  ATP  ATP+KLA
 NM_008524 lumican (Lum), mRNA [NM_008524] KLA 1.15 1.02 1.10 1.01 1.15 1.23 1.29
ATP 1.01 .91 1.01 1.06 1.04 .94 1.03
KLA/ATP 1.09 1.00 1.16 1.07 1.03 1.23 1.16
Map2k1
KLA  ATP  ATP+KLA
 NM_008927 mitogen-activated protein kinase kinase 1 (Map2k1), mRNA [NM_008927] KLA 1.82 2.00 2.31 2.03 2.51 2.20 1.51
ATP .99 1.14 .81 .87 .90 1.57 1.11
KLA/ATP 1.90 2.03 1.50 1.93 1.63 2.03 2.06
Map2k2
KLA  ATP  ATP+KLA
 NM_023138 mitogen-activated protein kinase kinase 2 (Map2k2), mRNA [NM_023138] KLA .96 1.01 1.09 .99 1.11 1.15 1.42
ATP 1.07 1.05 .74 .86 1.04 1.16 1.21
KLA/ATP 1.14 1.03 .68 .78 .85 1.01 1.20
Mapk1
KLA  ATP  ATP+KLA
 NM_001038663 mitogen-activated protein kinase 1 (Mapk1), transcript variant 2, mRNA [NM_001038663] KLA .97 1.03 .93 .86 .79 1.01 1.04
ATP .96 1.18 1.01 1.13 .84 1.04 1.16
KLA/ATP .99 .99 .84 .87 .63 .96 1.26
Mapk1
KLA  ATP  ATP+KLA
 NM_011949 mitogen-activated protein kinase 1 (Mapk1), transcript variant 1, mRNA [NM_011949] KLA .88 .80 .80 .73 .75 .76 .65
ATP .97 .96 1.06 .88 .90 .68 .48
KLA/ATP .82 .81 .78 .65 .64 .64 .45
Mapk11
KLA  ATP  ATP+KLA
 NM_011161 mitogen-activated protein kinase 11 (Mapk11), mRNA [NM_011161] KLA 1.28 1.30 1.41 1.46 1.58 1.29 .98
ATP .96 .95 .89 .82 .79 1.09 .85
KLA/ATP 1.44 1.42 1.32 1.23 1.23 .74 .66
Mapk12
KLA  ATP  ATP+KLA
 NM_013871 mitogen-activated protein kinase 12 (Mapk12), mRNA [NM_013871] KLA .94 .86 .87 .81 .77 .68 .49
ATP .97 .83 .92 .90 .86 .90 .51
KLA/ATP .91 .89 .88 .85 1.12 1.14 .53
Mapk13
KLA  ATP  ATP+KLA
 NM_011950 mitogen-activated protein kinase 13 (Mapk13), mRNA [NM_011950] KLA 1.22 1.21 1.35 1.26 1.24 1.13 1.01
ATP 1.08 1.00 1.20 1.20 1.13 1.22 1.39
KLA/ATP 1.22 1.27 1.30 1.30 1.21 1.11 1.47
Mapk14
KLA  ATP  ATP+KLA
 NM_011951 mitogen-activated protein kinase 14 (Mapk14), mRNA [NM_011951] KLA .70 .70 .62 .54 .67 .88 1.11
ATP 1.03 .98 .87 .69 .48 .78 .66
KLA/ATP .74 .68 .52 .46 .38 .45 .62
Mapk3
KLA  ATP  ATP+KLA
 NM_011952 mitogen-activated protein kinase 3 (Mapk3), mRNA [NM_011952] KLA .81 .85 .88 .72 .79 .73 .90
ATP 1.13 1.30 .92 1.48 1.08 .68 1.03
KLA/ATP 1.01 1.01 .66 1.13 .77 .77 1.16
Mdm2
KLA  ATP  ATP+KLA
 NM_010786 transformed mouse 3T3 cell double minute 2 (Mdm2), mRNA [NM_010786] KLA 1.77 1.59 1.98 1.51 1.77 1.60 1.77
ATP 1.01 1.21 1.36 3.24 5.04 2.08 1.36
KLA/ATP 1.89 1.86 2.93 5.65 5.98 2.78 2.64
Met
KLA  ATP  ATP+KLA
 NM_008591 met proto-oncogene (Met), mRNA [NM_008591] KLA 3.56 3.71 3.68 3.79 4.24 5.89 6.95
ATP .98 .96 1.16 1.21 3.32 12.98 6.60
KLA/ATP 3.75 3.80 3.58 3.28 3.69 4.27 14.22
Mm.13153
0
KLA  ATP  ATP+KLA
 161086915 Unknown KLA 1.00 1.07 1.14 1.08 .97 1.00 .93
ATP 1.04 .99 1.00 .95 .99 1.02 .90
KLA/ATP 1.08 1.18 1.14 1.16 1.04 1.06 1.08
Mm.19309
9
KLA  ATP  ATP+KLA
 46849811 Unknown KLA 1.32 1.36 1.42 1.17 1.06 .90 .58
ATP .98 1.12 1.41 1.81 1.44 1.14 .89
KLA/ATP 1.39 1.55 1.57 2.02 1.43 1.12 .74
Mm.21312
8
KLA  ATP  ATP+KLA
 141801344 Unknown KLA .96 .95 .83 .77 .52 .99 1.32
ATP .80 .82 1.09 .80 .83 1.19 1.46
KLA/ATP .78 .92 .98 .62 .71 .94 1.41
Mm.21516
1
KLA  ATP  ATP+KLA
 141801906 Unknown KLA 1.08 1.09 1.10 1.08 1.09 1.05 1.12
ATP .95 .94 1.05 1.16 1.05 1.08 1.14
KLA/ATP 1.07 1.15 1.16 1.16 1.10 1.14 1.14
Mm.22094
6
KLA  ATP  ATP+KLA
 27545180 Unknown KLA 1.00 .93 .97 1.05 1.06 1.29 1.13
ATP .90 .94 1.25 1.18 .85 .62 1.20
KLA/ATP .86 .99 1.14 .99 .83 .70 1.26
Mm.24600
3
KLA  ATP  ATP+KLA
 161086914 Unknown KLA 10.04 10.23 11.14 8.37 5.02 2.48 2.15
ATP .96 1.08 1.11 1.79 4.88 8.01 1.29
KLA/ATP 9.96 11.13 9.87 10.92 7.51 7.35 6.26
Mm.25381
9
KLA  ATP  ATP+KLA
 118130676 Unknown KLA 1.81 1.88 1.96 1.62 1.89 2.44 1.56
ATP .92 .91 1.24 1.01 1.16 2.06 1.95
KLA/ATP 1.62 1.86 1.86 1.41 1.89 2.37 1.97
Mm.26687
1
KLA  ATP  ATP+KLA
 80978931 Unknown KLA .67 .63 .70 .83 1.66 1.43 1.54
ATP 1.20 1.24 1.22 1.26 1.80 .81 1.02
KLA/ATP .63 .56 .83 1.06 1.26 .70 1.34
Mm.27304
9
KLA  ATP  ATP+KLA
 119672895 Unknown KLA .23 .22 .22 .22 .30 .51 .16
ATP 1.08 1.05 .88 .78 .47 .09 .20
KLA/ATP .28 .22 .21 .24 .26 .22 .12
Mm.27574
2
KLA  ATP  ATP+KLA
 112983655 Unknown KLA 1.35 1.16 .94 .85 .45 .33 .31
ATP .90 .86 1.17 1.09 1.18 1.21 .38
KLA/ATP 1.12 1.22 1.19 .91 .90 .83 .33
Mm.27970
KLA  ATP  ATP+KLA
 13994135 Unknown KLA 1.06 1.11 1.16 1.07 1.11 1.08 .95
ATP 1.02 1.09 1.05 1.05 .94 1.16 1.32
KLA/ATP 1.10 1.19 1.11 1.04 1.08 1.02 1.33
Mm.28968
1
KLA  ATP  ATP+KLA
 6754177 Unknown KLA 5.70 5.98 5.26 3.13 1.73 .87 .76
ATP 1.12 1.23 10.71 22.34 24.13 18.42 4.28
KLA/ATP 5.68 6.39 18.15 29.48 26.96 19.85 6.17
Mm.29002
2
KLA  ATP  ATP+KLA
 167234371 Unknown KLA .53 .50 .44 .38 .36 .39 .57
ATP 1.01 1.07 1.01 1.02 .84 .42 .40
KLA/ATP .53 .51 .38 .41 .47 .40 .21
Mm.29279
KLA  ATP  ATP+KLA
 171543834 Unknown KLA .71 .71 .59 .63 .49 .40 .28
ATP .81 .73 .76 .63 .48 .39 .26
KLA/ATP .57 .64 .60 .55 .54 .37 .32
Mm.33981
2
KLA  ATP  ATP+KLA
 6679780 Unknown KLA 1.10 1.14 1.09 1.05 1.05 1.08 1.01
ATP .95 1.06 2.35 11.15 2.46 1.50 1.03
KLA/ATP 1.02 1.05 2.05 8.78 2.65 1.76 1.02
Mm.38049
KLA  ATP  ATP+KLA
 118130391 Unknown KLA .67 .65 .73 .92 .63 .81 .76
ATP .93 .92 1.08 .54 .45 1.48 1.56
KLA/ATP .57 .65 .98 .67 .44 .78 1.16
Mm.44050
3
KLA  ATP  ATP+KLA
 149255105 Unknown KLA 1.04 .97 .97 .98 1.00 1.04 .96
ATP .97 .93 1.03 1.03 1.02 .98 .97
KLA/ATP .99 1.04 1.02 .89 .90 1.00 1.02
Mm.44463
KLA  ATP  ATP+KLA
 118129851 Unknown KLA 1.01 .98 .97 1.02 .93 1.06 1.05
ATP .97 1.01 1.04 1.06 1.02 1.08 .97
KLA/ATP 1.02 1.06 .95 1.04 1.09 1.14 1.03
Mm.45157
8
KLA  ATP  ATP+KLA
 124486802 Unknown KLA .91 1.00 .99 .96 1.05 .99 1.02
ATP .96 1.06 1.02 .95 1.02 1.02 .97
KLA/ATP 1.06 1.00 1.04 1.01 .97 .94 1.05
Mm.45825
9
KLA  ATP  ATP+KLA
 116292181 Unknown KLA .84 .86 .91 .85 .98 .98 1.00
ATP 1.05 1.06 .94 .95 1.00 .89 .89
KLA/ATP .92 .84 .87 .93 .91 .92 .82
Mm.47351
0
KLA  ATP  ATP+KLA
 162287332 Unknown KLA 4.46 4.82 5.29 4.00 2.26 1.25 1.10
ATP 1.24 1.72 1.02 2.08 1.66 2.53 .55
KLA/ATP 6.11 7.67 4.29 6.99 3.11 2.86 2.30
Mm.47526
5
KLA  ATP  ATP+KLA
 145046272 Unknown KLA 1.05 .97 .80 .91 .84 .88 .82
ATP .96 .81 1.14 .73 .64 1.00 .85
KLA/ATP .91 .89 .98 .66 .67 .78 .64
Mm.4769
KLA  ATP  ATP+KLA
 31542830 Unknown KLA .93 .99 .86 .85 .75 .83 .80
ATP 1.01 1.00 .91 .83 .96 1.15 .84
KLA/ATP .95 .95 .92 .81 .85 1.12 .87
Mm.5055
KLA  ATP  ATP+KLA
 145966820 Unknown KLA 1.04 .96 1.04 .97 1.00 1.00 .97
ATP .95 .97 .96 .95 .97 .97 .98
KLA/ATP .88 1.04 1.07 1.02 .97 .98 .96
Mm.56964
KLA  ATP  ATP+KLA
 144227223 Unknown KLA .96 .99 1.00 .99 .97 1.01 1.05
ATP .99 .94 1.00 .94 .97 .99 .91
KLA/ATP 1.05 .97 1.02 .97 .91 1.00 1.02
Mm.81698
KLA  ATP  ATP+KLA
 158937287 Unknown KLA .95 1.02 1.04 .98 1.01 1.04 1.08
ATP 1.00 1.03 .97 1.00 1.03 .98 .96
KLA/ATP 1.07 1.00 .94 .98 1.03 1.05 .97
Mmp2
KLA  ATP  ATP+KLA
 NM_008610 matrix metallopeptidase 2 (Mmp2), mRNA [NM_008610] KLA 1.12 1.24 1.48 1.26 1.44 1.19 1.09
ATP 1.05 1.01 1.07 1.08 .93 1.01 1.14
KLA/ATP 1.23 1.26 1.16 1.15 .95 1.11 1.04
Mmp9
KLA  ATP  ATP+KLA
 NM_013599 matrix metallopeptidase 9 (Mmp9), mRNA [NM_013599] KLA 1.49 1.65 1.43 1.32 1.46 1.33 2.10
ATP 1.03 1.05 1.12 1.36 1.17 2.27 5.92
KLA/ATP 1.51 1.64 1.35 1.78 1.34 1.20 2.96
Mras
KLA  ATP  ATP+KLA
 NM_008624 muscle and microspikes RAS (Mras), mRNA [NM_008624] KLA .77 .76 .75 .84 .92 .87 1.35
ATP 1.02 1.00 1.11 1.14 .87 .79 .80
KLA/ATP .77 .77 .86 .78 .69 .63 .61
Msn
KLA  ATP  ATP+KLA
 NM_010833 moesin (Msn), mRNA [NM_010833] KLA 1.50 1.65 1.89 1.55 1.91 1.89 1.87
ATP 1.12 1.47 .86 1.52 1.07 1.00 1.33
KLA/ATP 1.76 2.01 1.10 2.07 .92 1.16 1.66
Myc
KLA  ATP  ATP+KLA
 NM_010849 myelocytomatosis oncogene (Myc), mRNA [NM_010849] KLA .38 .31 .45 .45 .49 .35 .33
ATP 1.05 1.09 1.72 4.41 1.28 .45 .76
KLA/ATP .37 .30 .44 1.23 .34 .17 .19
Nanog
KLA  ATP  ATP+KLA
 AF507043 embryonic stem cell specific homeobox protein mRNA, complete cds [AF507043] KLA .98 .88 1.01 .97 1.01 1.05 1.10
ATP .96 .97 1.03 1.01 .95 .97 1.05
KLA/ATP .97 1.03 1.02 .99 1.00 1.09 1.03
Nras
KLA  ATP  ATP+KLA
 NM_010937 neuroblastoma ras oncogene (Nras), mRNA [NM_010937] KLA 1.20 1.22 1.27 1.20 1.09 .91 .84
ATP .98 .91 .69 .61 .59 .67 .78
KLA/ATP 1.22 1.14 .97 .79 .73 .61 .72
Nudt16l1
KLA  ATP  ATP+KLA
 NM_025839 nudix (nucleoside diphosphate linked moiety X)-type motif 16-like 1 (Nudt16l1), mRNA [NM_025839] KLA .61 .64 .64 .73 .81 .80 .69
ATP .99 1.02 .97 .93 .64 .65 .83
KLA/ATP .61 .65 .64 .72 .71 .57 .63
Pak1
KLA  ATP  ATP+KLA
 NM_011035 p21 (CDKN1A)-activated kinase 1 (Pak1), mRNA [NM_011035] KLA .72 .77 .79 .71 .67 .73 .95
ATP 1.10 1.07 .99 1.15 1.27 .62 .51
KLA/ATP .85 .83 .73 .76 .76 .55 .33
Pdcd4
KLA  ATP  ATP+KLA
 D86344 mRNA for Topoisomerase-inhibitor suppressed, complete cds. [D86344] KLA .77 .76 .74 .77 .69 .66 .56
ATP 1.02 1.08 1.06 1.18 1.09 .98 .50
KLA/ATP .84 .75 .87 .94 1.01 .96 .52
Pdk1
KLA  ATP  ATP+KLA
 AK165090 2 days pregnant adult female ovary cDNA, RIKEN full-length enriched library, clone:E330005M21 product:hypothetical protein, full insert sequence. [AK165090] KLA .86 .77 .71 .67 .45 .29 .35
ATP 1.06 .88 1.21 .72 .60 .26 .15
KLA/ATP .81 .74 .97 .57 .51 .22 .09
Pdk1
KLA  ATP  ATP+KLA
 NM_172665 pyruvate dehydrogenase kinase, isoenzyme 1 (Pdk1), nuclear gene encoding mitochondrial protein, mRNA [NM_172665] KLA .92 .94 .91 .79 .63 .46 .51
ATP .95 1.03 1.06 1.02 .63 .31 .37
KLA/ATP .88 .91 .91 .89 .62 .31 .27
Pik3ca
KLA  ATP  ATP+KLA
 ENSMUST00000108243 ens|Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (EC 2.7.1.153) (PI3-kinase p110 subunit alpha) (PtdIns-3- kinase p110) (PI3K). [Source:Uniprot/SWISSPROT;Acc:P42337] [ENSMUST00000108243] KLA 1.07 1.01 .91 .90 .98 .96 .86
ATP 1.03 .87 1.12 .63 1.22 1.86 .60
KLA/ATP 1.05 .82 .91 .61 1.17 1.26 .63
Pik3ca
KLA  ATP  ATP+KLA
 NM_008839 phosphatidylinositol 3-kinase, catalytic, alpha polypeptide (Pik3ca), mRNA [NM_008839] KLA 1.15 1.11 1.05 .82 .99 1.03 1.27
ATP .98 1.00 .79 .75 .96 1.32 1.10
KLA/ATP 1.10 .98 .64 .72 .80 1.20 1.41
Pik3cb
KLA  ATP  ATP+KLA
 NM_029094 phosphatidylinositol 3-kinase, catalytic, beta polypeptide (Pik3cb), mRNA [NM_029094] KLA 1.06 1.06 1.03 .73 .68 .98 1.69
ATP 1.04 1.21 .95 1.02 .85 .93 1.73
KLA/ATP 1.15 1.27 .73 .83 .58 .81 1.81
Pik3cd
KLA  ATP  ATP+KLA
 NM_008840 phosphatidylinositol 3-kinase catalytic delta polypeptide (Pik3cd), transcript variant 1, mRNA [NM_008840] KLA 2.28 2.42 3.10 4.17 3.35 2.31 1.34
ATP 1.02 .91 .99 .63 .30 .67 .80
KLA/ATP 2.14 2.23 2.70 1.51 1.17 .85 .72
Pik3cd
KLA  ATP  ATP+KLA
 U86587 phosphatidylinositol 3-kinase catalytic subunit p110 delta mRNA, complete cds. [U86587] KLA 2.21 2.24 3.71 3.17 3.67 2.66 1.48
ATP 1.00 1.03 .93 .96 .46 .75 .97
KLA/ATP 2.27 2.32 1.97 2.02 1.01 .99 .98
Pik3cg
KLA  ATP  ATP+KLA
 NM_020272 phosphoinositide-3-kinase, catalytic, gamma polypeptide (Pik3cg), mRNA [NM_020272] KLA .53 .53 .61 .64 .97 .86 .79
ATP 1.01 1.13 .88 .89 .52 .53 .53
KLA/ATP .58 .53 .43 .60 .40 .43 .62
Pik3r1
KLA  ATP  ATP+KLA
 NM_001077495 phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 alpha) (Pik3r1), transcript variant 2, mRNA [NM_001077495] KLA 1.05 1.07 1.03 1.00 1.01 1.20 .85
ATP .97 1.02 1.48 1.42 1.76 1.33 1.23
KLA/ATP 1.11 1.12 1.06 1.17 1.24 .99 1.12
Pik3r2
KLA  ATP  ATP+KLA
 NM_008841 phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 2 (p85 beta) (Pik3r2), mRNA [NM_008841] KLA .50 .50 .48 .43 .46 .66 .75
ATP .78 .68 .45 .43 .28 .57 1.37
KLA/ATP .49 .38 .32 .33 .38 .67 1.10
Pik3r3
KLA  ATP  ATP+KLA
 NM_181585 phosphatidylinositol 3 kinase, regulatory subunit, polypeptide 3 (p55) (Pik3r3), mRNA [NM_181585] KLA 1.59 1.49 1.37 1.17 1.05 1.55 1.41
ATP 1.12 1.00 1.33 1.70 2.01 2.37 2.02
KLA/ATP 1.63 1.54 1.58 1.70 2.43 2.68 1.92
Pik3r5
KLA  ATP  ATP+KLA
 NM_177320 phosphoinositide-3-kinase, regulatory subunit 5, p101 (Pik3r5), mRNA [NM_177320] KLA 3.57 3.58 4.16 3.54 4.11 2.59 2.39
ATP 1.08 1.08 .93 1.67 3.11 1.88 1.34
KLA/ATP 3.91 3.70 3.30 3.80 2.70 2.04 3.00
Plau
KLA  ATP  ATP+KLA
 NM_008873 plasminogen activator, urokinase (Plau), mRNA [NM_008873] KLA .28 .27 .22 .23 .19 .25 .27
ATP .99 1.19 1.63 2.44 1.52 .49 1.12
KLA/ATP .26 .29 .32 .40 .35 .32 .48
Plaur
KLA  ATP  ATP+KLA
 NM_011113 plasminogen activator, urokinase receptor (Plaur), mRNA [NM_011113] KLA 2.40 2.61 2.30 1.95 1.60 .80 .47
ATP 1.08 1.28 1.24 2.13 2.75 4.78 2.70
KLA/ATP 2.66 3.04 2.56 3.92 2.64 3.10 2.81
Plce1
KLA  ATP  ATP+KLA
 AK035546 adult male urinary bladder cDNA, RIKEN full-length enriched library, clone:9530064F18 product:PANCREAS-ENRICHED PHOSPHOLIPASE C homolog [Homo sapiens], full insert sequence. [AK035546] KLA .99 1.08 1.03 1.00 1.06 1.04 .97
ATP 1.04 1.01 1.02 1.01 .96 1.01 1.06
KLA/ATP .98 .98 .93 1.02 .95 .93 .97
Plce1
KLA  ATP  ATP+KLA
 BC025027 phospholipase C, epsilon 1, mRNA (cDNA clone IMAGE:4948638), with apparent retained intron. [BC025027] KLA 1.07 1.12 1.04 1.10 1.07 1.04 1.04
ATP 1.00 .96 1.06 .99 .98 .96 1.01
KLA/ATP 1.21 1.06 1.13 1.09 1.00 1.08 1.14
Plce1
KLA  ATP  ATP+KLA
 NM_019588 phospholipase C, epsilon 1 (Plce1), mRNA [NM_019588] KLA .98 1.03 .99 .96 1.01 1.04 .96
ATP .98 .99 1.02 1.13 .99 1.01 1.00
KLA/ATP .97 1.11 1.00 1.07 .93 1.06 .99
Plcg2
KLA  ATP  ATP+KLA
 NM_172285 phospholipase C, gamma 2 (Plcg2), mRNA [NM_172285] KLA .76 .74 .68 .66 .71 .92 .95
ATP .96 .90 .95 .87 .81 .79 .91
KLA/ATP .76 .71 .69 .62 .72 .78 .68
Ppp1ca
KLA  ATP  ATP+KLA
 NM_031868 protein phosphatase 1, catalytic subunit, alpha isoform (Ppp1ca), mRNA [NM_031868] KLA .89 .93 .93 .86 .95 1.07 1.20
ATP 1.04 1.07 .93 1.02 1.01 .89 1.10
KLA/ATP .98 .93 .74 .91 .84 1.01 1.34
Ppp1cb
KLA  ATP  ATP+KLA
 NM_172707 protein phosphatase 1, catalytic subunit, beta isoform (Ppp1cb), mRNA [NM_172707] KLA 1.12 1.08 1.05 1.02 .89 .84 .94
ATP .89 .87 .75 .55 .73 1.14 .69
KLA/ATP .92 .94 .80 .64 .64 .83 .65
Ppp1cc
KLA  ATP  ATP+KLA
 NM_013636 protein phosphatase 1, catalytic subunit, gamma isoform (Ppp1cc), mRNA [NM_013636] KLA .51 .51 .49 .48 .53 .64 .64
ATP 1.02 1.01 .85 .79 .72 .89 .95
KLA/ATP .54 .49 .42 .43 .56 .76 .81
Ppp1r12a
KLA  ATP  ATP+KLA
 AK077739 8 days embryo whole body cDNA, RIKEN full-length enriched library, clone:5730577I22 product:inferred: myosin phosphatase, target subunit 1, full insert sequence [AK077739] KLA 1.91 1.98 2.00 2.00 1.63 1.58 1.17
ATP .93 .80 .82 .46 1.01 1.29 .79
KLA/ATP 1.82 1.80 1.85 .91 1.54 1.51 .90
Ppp1r12a
KLA  ATP  ATP+KLA
 NM_027892 protein phosphatase 1, regulatory (inhibitor) subunit 12A (Ppp1r12a), mRNA [NM_027892] KLA 2.36 2.42 2.34 2.71 1.96 2.11 1.93
ATP .87 .85 1.00 .98 1.75 4.57 2.89
KLA/ATP 2.02 2.24 2.59 1.90 2.16 4.01 5.77
Ppp1r12b
KLA  ATP  ATP+KLA
 AK132310 15 days embryo head cDNA, RIKEN full-length enriched library, clone:4022402N03 product:unclassifiable, full insert sequence [AK132310] KLA .82 .86 .71 .94 1.26 1.84 5.38
ATP 1.02 1.07 1.17 1.23 1.24 1.58 1.53
KLA/ATP .83 .82 .82 .84 .80 1.51 3.05
Ppp1r12b
KLA  ATP  ATP+KLA
 NM_001081307 protein phosphatase 1, regulatory (inhibitor) subunit 12B (Ppp1r12b), mRNA [NM_001081307] KLA .78 .80 .80 .75 .85 .79 .91
ATP .87 .83 .89 .75 1.01 .88 1.04
KLA/ATP .74 .73 .78 .71 .88 .86 .89
Prkaca
KLA  ATP  ATP+KLA
 NM_008854 protein kinase, cAMP dependent, catalytic, alpha (Prkaca), mRNA [NM_008854] KLA .71 .74 .72 .70 .72 .84 .85
ATP 1.05 .98 .89 .92 .76 .60 1.02
KLA/ATP .79 .74 .55 .65 .60 .65 .93
Prkacb
KLA  ATP  ATP+KLA
 NM_011100 protein kinase, cAMP dependent, catalytic, beta (Prkacb), mRNA [NM_011100] KLA .69 .70 .66 .58 .51 .55 .59
ATP 1.02 1.19 .97 1.01 .69 .38 .56
KLA/ATP .72 .73 .57 .62 .47 .41 .45
Prkca
KLA  ATP  ATP+KLA
 NM_011101 protein kinase C, alpha (Prkca), mRNA [NM_011101] KLA 1.00 .96 .94 .95 .95 .89 .96
ATP 1.00 1.03 .91 .94 .82 .87 1.13
KLA/ATP 1.02 .95 .91 .86 .78 .84 .94
Prkcb1
KLA  ATP  ATP+KLA
 NM_008855 protein kinase C, beta 1 (Prkcb1), mRNA [NM_008855] KLA .92 .95 .93 .78 .77 1.08 1.83
ATP 1.03 1.12 1.09 1.23 .90 2.08 .96
KLA/ATP .98 .99 .82 .89 .62 1.01 1.08
Prkcc
KLA  ATP  ATP+KLA
 NM_011102 protein kinase C, gamma (Prkcc), mRNA [NM_011102] KLA 1.02 1.04 1.11 1.04 .96 1.02 1.05
ATP .98 .98 1.05 1.03 1.08 .96 .95
KLA/ATP 1.21 1.16 1.09 1.07 1.04 .98 .93
Prkx
KLA  ATP  ATP+KLA
 NM_016979 protein kinase, X-linked (Prkx), mRNA [NM_016979] KLA 3.61 3.79 4.67 4.66 4.85 4.19 1.43
ATP .98 .90 .63 .61 1.12 1.90 1.29
KLA/ATP 3.56 3.36 2.62 2.06 2.26 2.87 2.31
Ptch1
KLA  ATP  ATP+KLA
 AK147626 cDNA, RIKEN full-length enriched library, clone:M5C1096C04 product:patched homolog 1, full insert sequence [AK147626] KLA 1.35 1.31 1.25 1.03 1.06 .89 .89
ATP 1.00 1.08 1.01 .90 1.09 1.20 1.03
KLA/ATP 1.27 1.29 1.34 1.24 1.22 1.21 1.01
Ptch1
KLA  ATP  ATP+KLA
 NM_008957 patched homolog 1 (Ptch1), mRNA [NM_008957] KLA 1.10 1.05 1.10 1.03 .99 .99 1.01
ATP 1.02 1.01 1.04 1.01 1.07 1.14 1.05
KLA/ATP 1.12 1.10 1.05 1.08 1.06 1.11 .98
Ptk2
KLA  ATP  ATP+KLA
 NM_007982 PTK2 protein tyrosine kinase 2 (Ptk2), mRNA [NM_007982] KLA .99 .99 1.02 1.04 1.09 1.22 1.57
ATP 1.04 1.09 .95 .98 .67 .96 .87
KLA/ATP .99 1.03 .87 .93 .81 1.16 1.04
Ptpn11
KLA  ATP  ATP+KLA
 NM_001109992 protein tyrosine phosphatase, non-receptor type 11 (Ptpn11), transcript variant 2, mRNA [NM_001109992] KLA 1.52 1.71 1.59 1.78 1.62 1.57 1.35
ATP 1.04 .93 .86 .79 1.09 1.95 1.90
KLA/ATP 1.59 1.61 1.45 1.11 1.18 1.82 3.02
Ptpn11
KLA  ATP  ATP+KLA
 NM_011202 protein tyrosine phosphatase, non-receptor type 11 (Ptpn11), transcript variant 1, mRNA [NM_011202] KLA 1.32 1.28 1.17 1.21 1.18 1.06 1.05
ATP .97 .77 .71 .56 .90 1.27 1.04
KLA/ATP 1.22 1.21 1.02 .70 .96 1.06 .94
Ptpn6
KLA  ATP  ATP+KLA
 NM_001077705 protein tyrosine phosphatase, non-receptor type 6 (Ptpn6), transcript variant 2, mRNA [NM_001077705] KLA .87 .90 1.03 1.05 1.83 1.96 2.34
ATP 1.06 1.09 .94 1.08 .51 .34 1.04
KLA/ATP .98 .93 .71 .95 .67 .64 1.44
Ptpn6
KLA  ATP  ATP+KLA
 NM_013545 protein tyrosine phosphatase, non-receptor type 6 (Ptpn6), transcript variant 1, mRNA [NM_013545] KLA 1.24 1.20 1.46 1.42 2.43 2.27 2.10
ATP 1.18 1.20 1.10 1.49 .80 .58 1.09
KLA/ATP 1.36 1.42 1.27 1.66 1.12 .87 1.46
Ptpn6
KLA  ATP  ATP+KLA
 S63763 gb|me/Hcph (mev)=viable motheaten/hematopoietic cell protein-tyrosine phosphatase {insertion} [mice, mRNA Partial Mutant, 120 nt]. [S63763] KLA 1.06 1.03 1.12 1.14 1.11 1.01 1.09
ATP 1.03 .97 .96 .90 .89 1.17 1.76
KLA/ATP 1.07 1.00 1.03 .98 1.00 1.29 1.44
Pxn
KLA  ATP  ATP+KLA
 AK084243 12 days embryo eyeball cDNA, RIKEN full-length enriched library, clone:D230012N01 product:inferred: paxillin beta {Homo sapiens}, full insert sequence. [AK084243] KLA 1.06 .92 1.01 .95 .97 .97 1.02
ATP 1.02 1.02 .97 .90 .98 .94 .89
KLA/ATP .96 .97 .98 .91 1.01 1.00 .94
Pxn
KLA  ATP  ATP+KLA
 NM_133915 paxillin (Pxn), transcript variant beta, mRNA [NM_133915] KLA 1.13 1.13 1.14 1.14 1.49 1.60 1.30
ATP 1.11 1.22 .86 1.04 1.14 1.18 1.35
KLA/ATP 1.41 1.22 .80 .92 1.07 1.54 2.60
Rac1
KLA  ATP  ATP+KLA
 NM_009007 RAS-related C3 botulinum substrate 1 (Rac1), mRNA [NM_009007] KLA 1.02 1.01 1.02 .99 1.03 1.15 1.08
ATP .99 1.15 1.01 1.27 1.06 1.20 1.06
KLA/ATP 1.00 1.04 .88 1.16 .91 1.21 1.38
Raf1
KLA  ATP  ATP+KLA
 AK036317 16 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:9630056E02 product:v-raf-1 leukemia viral oncogene 1, full insert sequence. [AK036317] KLA 1.47 1.34 1.55 1.29 1.59 1.32 1.46
ATP 1.05 .98 .54 .63 3.32 2.07 1.01
KLA/ATP 1.57 1.33 .79 .96 2.26 1.38 1.35
Raf1
KLA  ATP  ATP+KLA
 NM_029780 v-raf-leukemia viral oncogene 1 (Raf1), mRNA [NM_029780] KLA 1.65 1.64 1.93 1.77 1.77 1.72 1.81
ATP .95 .96 .83 .80 2.22 2.92 1.19
KLA/ATP 1.68 1.64 1.39 1.32 1.85 2.50 2.06
Rdx
KLA  ATP  ATP+KLA
 AK085332 0 day neonate kidney cDNA, RIKEN full-length enriched library, clone:D630012L19 product:unclassifiable, full insert sequence [AK085332] KLA .97 .94 .92 .94 .91 .97 .93
ATP .97 .94 .99 1.03 .94 .99 .91
KLA/ATP .93 1.00 .96 .95 .90 .91 .90
Rdx
KLA  ATP  ATP+KLA
 NM_009041 radixin (Rdx), transcript variant 1, mRNA [NM_009041] KLA 1.27 1.41 1.40 1.39 1.00 .64 .68
ATP 1.02 1.21 1.02 .99 .82 .89 .63
KLA/ATP 1.38 1.49 1.22 1.25 .88 .77 .79
Rhoa
KLA  ATP  ATP+KLA
 NM_016802 ras homolog gene family, member A (Rhoa), mRNA [NM_016802] KLA .93 1.00 1.07 .97 1.08 1.06 1.02
ATP .93 .88 .49 .61 .63 .78 1.05
KLA/ATP .94 .92 .59 .63 .61 .78 1.12
Rnasen
KLA  ATP  ATP+KLA
 AK077549 8 days embryo whole body cDNA, RIKEN full-length enriched library, clone:5730445E20 product:weakly similar to RIBONUCLEASE III (EC 3.1.26.3) (RNASE III) (P241) [Homo sapiens], full insert sequence. [AK077549] KLA .87 .93 .98 .96 .88 1.01 1.03
ATP 1.09 1.05 1.15 .91 .77 .98 1.68
KLA/ATP .84 .99 .92 .84 .80 .91 1.18
Rnasen
KLA  ATP  ATP+KLA
 NM_026799 ribonuclease III, nuclear (Rnasen), mRNA [NM_026799] KLA .89 .90 .95 .99 1.01 1.30 1.09
ATP .94 .86 .94 .77 .55 .67 1.15
KLA/ATP .86 .86 .86 .68 .54 .85 1.39
Rock1
KLA  ATP  ATP+KLA
 NM_009071 Rho-associated coiled-coil containing protein kinase 1 (Rock1), mRNA [NM_009071] KLA 2.40 2.48 2.37 3.07 1.94 1.42 1.21
ATP .95 .92 .87 .70 1.13 1.74 .98
KLA/ATP 2.27 2.35 2.56 1.60 1.65 1.56 1.23
Rock2
KLA  ATP  ATP+KLA
 NM_009072 Rho-associated coiled-coil containing protein kinase 2 (Rock2), mRNA [NM_009072] KLA .99 .92 .83 .87 .73 .74 1.04
ATP 1.07 1.31 1.16 1.02 1.02 1.03 .88
KLA/ATP 1.00 1.07 .93 .85 .69 .63 .81
Rps6
KLA  ATP  ATP+KLA
 AK013825 adult male hippocampus cDNA, RIKEN full-length enriched library, clone:2900086I01 product:ribosomal protein S6, full insert sequence. [AK013825] KLA 1.04 1.06 1.03 .99 .94 .96 1.26
ATP 1.01 1.00 1.04 .99 .99 .94 1.12
KLA/ATP 1.02 1.08 .95 1.04 .94 .97 .90
Rps6
KLA  ATP  ATP+KLA
 NM_009096 ribosomal protein S6 (Rps6), mRNA [NM_009096] KLA 1.01 1.01 .94 .87 .89 .66 .72
ATP 1.11 1.07 1.10 1.12 1.12 1.03 .47
KLA/ATP .96 1.04 1.22 1.10 .86 .84 .40
Rps6kb1
KLA  ATP  ATP+KLA
 NM_001114334 ribosomal protein S6 kinase, polypeptide 1 (Rps6kb1), transcript variant 1, mRNA [NM_001114334] KLA .99 1.00 .90 .89 .99 .99 .92
ATP 1.01 .96 1.00 .79 1.36 1.19 .72
KLA/ATP 1.08 .99 .93 .92 1.18 .90 .56
Rps6kb1
KLA  ATP  ATP+KLA
 NM_028259 ribosomal protein S6 kinase, polypeptide 1 (Rps6kb1), transcript variant 2, mRNA [NM_028259] KLA 1.01 .93 1.07 1.04 .99 .99 .98
ATP 1.09 1.05 1.00 1.01 1.08 1.03 1.03
KLA/ATP 1.07 1.04 .94 .98 1.03 1.05 1.05
Rps6kb2
KLA  ATP  ATP+KLA
 AK090093 kidney CCL-142 RAG cDNA, RIKEN full-length enriched library, clone:G430107K15 product:ribosomal protein S6 kinase, 70kD, polypeptide 2, full insert sequence [AK090093] KLA .97 1.01 .98 .97 .98 1.04 1.07
ATP 1.00 1.08 1.06 1.09 1.11 1.06 1.03
KLA/ATP 1.05 .96 .86 1.03 1.40 1.07 .99
Rps6kb2
KLA  ATP  ATP+KLA
 NM_021485 ribosomal protein S6 kinase, polypeptide 2 (Rps6kb2), mRNA [NM_021485] KLA 1.36 1.40 1.45 1.40 1.63 1.57 1.46
ATP 1.08 1.19 .97 1.15 .90 .99 1.34
KLA/ATP 1.44 1.55 1.09 1.39 1.00 1.12 1.77
Rras
KLA  ATP  ATP+KLA
 NM_009101 Harvey rat sarcoma oncogene, subgroup R (Rras), mRNA [NM_009101] KLA .89 .89 .99 .98 1.25 1.48 1.81
ATP 1.14 1.17 1.01 1.61 1.37 1.33 1.40
KLA/ATP 1.09 1.05 1.01 1.34 1.24 1.10 1.27
Rras2
KLA  ATP  ATP+KLA
 NM_025846 related RAS viral (r-ras) oncogene homolog 2 (Rras2), mRNA [NM_025846] KLA 7.72 7.35 7.03 5.47 3.21 1.03 .65
ATP .92 .86 .99 .95 1.86 2.13 .72
KLA/ATP 6.51 6.50 5.94 4.45 3.05 1.72 .75
Sdc1
KLA  ATP  ATP+KLA
 NM_011519 syndecan 1 (Sdc1), mRNA [NM_011519] KLA 1.40 1.34 1.52 1.50 1.64 2.31 2.39
ATP 1.20 1.20 1.28 2.62 10.61 16.35 9.95
KLA/ATP 1.61 1.71 1.60 3.94 11.52 15.28 20.29
Sdc2
KLA  ATP  ATP+KLA
 NM_008304 syndecan 2 (Sdc2), mRNA [NM_008304] KLA .93 1.00 .95 .89 .96 .93 .89
ATP 1.01 .98 .99 .99 .93 .96 .97
KLA/ATP .93 .91 1.05 .92 .92 .94 .89
Sdc4
KLA  ATP  ATP+KLA
 NM_011521 syndecan 4 (Sdc4), mRNA [NM_011521] KLA 11.43 12.18 10.95 10.65 8.99 5.55 1.88
ATP 1.01 1.13 1.24 3.44 3.56 2.85 2.00
KLA/ATP 11.15 13.40 11.98 16.31 11.68 6.11 4.76
Slc9a1
KLA  ATP  ATP+KLA
 NM_016981 solute carrier family 9 (sodium/hydrogen exchanger), member 1 (Slc9a1), mRNA [NM_016981] KLA 1.74 1.72 1.95 1.84 1.86 1.53 1.49
ATP 1.11 1.28 .95 1.46 1.98 2.67 1.47
KLA/ATP 1.85 2.02 1.70 2.47 2.18 3.18 3.48
Slc9a1
KLA  ATP  ATP+KLA
 U51112 Na+/H+ exchanger (NHE-1) mRNA, complete cds. [U51112] KLA 1.78 1.83 2.11 1.90 1.91 1.61 1.40
ATP 1.07 1.14 .98 1.54 2.00 2.85 1.44
KLA/ATP 1.97 2.16 2.01 2.44 2.30 3.37 3.15
Smad2
KLA  ATP  ATP+KLA
 NM_010754 MAD homolog 2 (Drosophila) (Smad2), mRNA [NM_010754] KLA 1.05 1.08 1.04 1.17 1.40 1.43 1.59
ATP 1.01 1.02 1.16 1.14 1.15 1.32 1.34
KLA/ATP 1.00 .99 .97 1.09 1.40 1.14 1.40
Smo
KLA  ATP  ATP+KLA
 NM_176996 smoothened homolog (Drosophila) (Smo), mRNA [NM_176996] KLA .67 .64 .53 .53 .39 .30 .20
ATP .78 .69 .74 .61 .43 .30 .21
KLA/ATP .56 .53 .57 .51 .42 .29 .24
Sos1
KLA  ATP  ATP+KLA
 NM_009231 Son of sevenless homolog 1 (Drosophila) (Sos1), mRNA [NM_009231] KLA 2.36 2.40 3.42 3.15 2.78 1.81 1.71
ATP .99 1.00 .99 1.15 1.14 1.25 1.24
KLA/ATP 2.41 2.26 1.95 2.44 1.47 1.66 1.37
Sos2
KLA  ATP  ATP+KLA
 XM_127051 gb|PREDICTED: Mus musculus Son of sevenless homolog 2 (Drosophila) (Sos2), mRNA [XM_127051] KLA .81 .77 .79 .92 1.04 1.06 1.20
ATP 1.00 1.00 1.09 .79 .68 .81 .94
KLA/ATP .77 .69 .71 .60 .64 .77 1.07
Src
KLA  ATP  ATP+KLA
 NM_009271 Rous sarcoma oncogene (Src), transcript variant 1, mRNA [NM_009271] KLA 6.99 7.23 7.54 5.99 5.34 3.39 3.00
ATP 1.02 1.06 1.06 2.08 4.41 5.03 3.97
KLA/ATP 7.44 7.51 5.48 6.24 4.86 5.86 7.90
Stat3
KLA  ATP  ATP+KLA
 NM_213659 signal transducer and activator of transcription 3 (Stat3), transcript variant 1, mRNA [NM_213659] KLA 4.36 4.42 4.67 6.02 4.95 3.45 1.46
ATP 1.01 .97 1.07 1.17 2.47 4.04 1.47
KLA/ATP 4.02 4.57 6.65 6.51 7.06 7.39 3.61
Tcfap4
KLA  ATP  ATP+KLA
 NM_031182 transcription factor AP4 (Tcfap4), mRNA [NM_031182] KLA .61 .69 .68 .72 .65 .76 .75
ATP .93 .96 .88 .88 .69 .66 .67
KLA/ATP .62 .67 .70 .71 .68 .66 .66
Tgfb1
KLA  ATP  ATP+KLA
 NM_011577 transforming growth factor, beta 1 (Tgfb1), mRNA [NM_011577] KLA .87 .89 .90 .70 .83 .77 1.12
ATP 1.20 1.41 .80 1.49 1.11 .93 .99
KLA/ATP 1.10 1.20 .53 1.05 .66 .85 .90
Tgfb2
KLA  ATP  ATP+KLA
 NM_009367 transforming growth factor, beta 2 (Tgfb2), mRNA [NM_009367] KLA 1.01 .91 .98 .98 .92 1.19 .96
ATP .99 1.03 1.00 1.02 .99 1.07 .93
KLA/ATP 1.02 .99 1.03 .98 1.04 1.06 .96
Thbs1
KLA  ATP  ATP+KLA
 NM_011580 thrombospondin 1 (Thbs1), mRNA [NM_011580] KLA 2.22 2.22 2.74 3.10 4.57 7.17 7.22
ATP 1.16 2.53 8.45 12.26 15.50 43.06 35.83
KLA/ATP 2.46 3.43 8.29 17.50 28.16 46.17 54.67
Tiam1
KLA  ATP  ATP+KLA
 NM_009384 T-cell lymphoma invasion and metastasis 1 (Tiam1), mRNA [NM_009384] KLA 1.72 1.71 2.10 1.75 1.43 .71 .27
ATP 1.04 1.03 .79 .88 .90 .72 1.07
KLA/ATP 1.79 1.84 1.46 1.43 .90 .87 .73
Timp3
KLA  ATP  ATP+KLA
 NM_011595 tissue inhibitor of metalloproteinase 3 (Timp3), mRNA [NM_011595] KLA 1.09 1.25 1.18 1.12 1.19 1.18 1.04
ATP .97 .96 1.15 1.49 1.81 1.57 1.48
KLA/ATP 1.16 1.25 1.13 1.61 1.85 1.89 1.24
Tlr2
KLA  ATP  ATP+KLA
 NM_011905 toll-like receptor 2 (Tlr2), mRNA [NM_011905] KLA 13.65 11.82 8.87 7.95 4.67 2.78 2.33
ATP 1.06 1.24 2.76 6.28 11.55 13.82 .67
KLA/ATP 13.11 12.91 14.48 13.84 14.18 11.14 2.78
Tlr4
KLA  ATP  ATP+KLA
 NM_021297 toll-like receptor 4 (Tlr4), mRNA [NM_021297] KLA .69 .61 .75 .94 .64 .81 .73
ATP .95 .90 1.12 .56 .47 1.51 1.53
KLA/ATP .57 .62 1.01 .64 .39 .73 1.13
Tnf
KLA  ATP  ATP+KLA
 NM_013693 tumor necrosis factor (Tnf), mRNA [NM_013693] KLA 13.35 12.76 10.71 9.03 10.64 7.39 8.32
ATP 2.01 2.48 8.27 19.20 9.72 4.09 1.49
KLA/ATP 12.72 15.76 12.73 17.34 5.10 3.61 6.07
Trp53
KLA  ATP  ATP+KLA
 NM_011640 transformation related protein 53 (Trp53), mRNA [NM_011640] KLA 1.25 1.37 1.11 .86 .72 .71 .95
ATP 1.15 1.32 .90 1.85 1.26 .68 .70
KLA/ATP 1.66 1.49 .80 1.76 .81 .65 .74
Twist1
KLA  ATP  ATP+KLA
 NM_011658 twist gene homolog 1 (Drosophila) (Twist1), mRNA [NM_011658] KLA 1.03 1.04 1.03 1.00 1.02 .98 1.05
ATP 1.00 .98 .99 1.02 .99 1.02 1.05
KLA/ATP 1.08 .99 1.01 1.06 1.07 1.09 1.02
Twist2
KLA  ATP  ATP+KLA
 NM_007855 twist homolog 2 (Drosophila) (Twist2), mRNA [NM_007855] KLA 1.02 1.02 .95 1.03 .98 .96 1.03
ATP 1.02 .97 1.06 1.09 1.00 .96 1.02
KLA/ATP .99 1.03 1.02 1.00 1.10 1.07 1.01
Vav2
KLA  ATP  ATP+KLA
 BC053060 vav 2 oncogene, mRNA (cDNA clone MGC:62363 IMAGE:5704852), complete cds [BC053060] KLA .73 .58 .55 1.16 .76 1.35 1.75
ATP .99 .89 .79 .82 .67 .85 1.09
KLA/ATP .64 .63 .61 .65 .66 .80 1.23
Vav2
KLA  ATP  ATP+KLA
 NM_009500 vav 2 oncogene (Vav2), mRNA [NM_009500] KLA .98 1.05 .98 .99 1.02 1.36 1.43
ATP 1.07 1.06 .96 1.01 .89 .95 1.08
KLA/ATP 1.04 1.05 .98 1.03 .88 .99 1.13
Vegfa
KLA  ATP  ATP+KLA
 NM_001025250 vascular endothelial growth factor A (Vegfa), transcript variant 1, mRNA [NM_001025250] KLA .49 .48 .46 .46 .39 .64 1.18
ATP 1.05 1.37 3.82 10.55 12.51 24.20 7.85
KLA/ATP .48 .59 1.45 7.42 19.75 27.42 22.35
Vegfa
KLA  ATP  ATP+KLA
 NM_001025257 vascular endothelial growth factor A (Vegfa), transcript variant 3, mRNA [NM_001025257] KLA .72 .71 .66 .70 .65 .80 1.22
ATP 1.01 1.21 3.24 11.12 11.09 18.59 5.43
KLA/ATP .68 .71 1.47 5.94 15.06 20.32 17.31
Vtn
KLA  ATP  ATP+KLA
 NM_011707 vitronectin (Vtn), mRNA [NM_011707] KLA 1.05 1.05 1.01 1.00 .97 1.04 .95
ATP .94 .99 1.00 .94 .96 1.04 1.09
KLA/ATP .97 1.00 1.02 .99 .98 .94 .98
Wnt1
KLA  ATP  ATP+KLA
 NM_021279 wingless-related MMTV integration site 1 (Wnt1), mRNA [NM_021279] KLA 1.01 1.01 1.05 1.03 1.04 1.04 1.01
ATP .99 .99 1.01 .97 .96 1.01 1.00
KLA/ATP 1.01 1.04 1.06 1.02 1.00 .98 .98
Wnt10a
KLA  ATP  ATP+KLA
 NM_009518 wingless related MMTV integration site 10a (Wnt10a), mRNA [NM_009518] KLA 1.73 1.66 1.33 1.17 1.10 1.02 1.03
ATP 1.03 1.04 .93 1.02 1.04 1.07 1.06
KLA/ATP 1.83 1.67 1.53 1.21 1.10 1.12 1.09
Wnt10b
KLA  ATP  ATP+KLA
 NM_011718 wingless related MMTV integration site 10b (Wnt10b), mRNA [NM_011718] KLA 1.10 .98 1.13 1.01 .96 1.00 .96
ATP 1.02 1.02 .99 1.01 .96 1.02 1.01
KLA/ATP 1.01 1.18 .97 .97 1.03 1.04 .98
Wnt11
KLA  ATP  ATP+KLA
 NM_009519 wingless-related MMTV integration site 11 (Wnt11), mRNA [NM_009519] KLA .97 1.00 .97 1.03 1.16 1.08 1.11
ATP 1.03 1.06 1.08 1.23 1.13 1.03 1.08
KLA/ATP .95 1.00 .95 1.02 .97 1.04 1.04
Wnt16
KLA  ATP  ATP+KLA
 NM_053116 wingless-related MMTV integration site 16 (Wnt16), mRNA [NM_053116] KLA 1.00 1.02 .97 1.02 .96 1.02 1.05
ATP 1.01 1.00 .97 .98 .97 .95 1.02
KLA/ATP .96 1.01 .98 1.03 .99 1.00 .97
Wnt2
KLA  ATP  ATP+KLA
 NM_023653 wingless-related MMTV integration site 2 (Wnt2), mRNA [NM_023653] KLA 1.01 1.00 1.02 .96 1.06 1.03 .94
ATP .97 1.01 1.02 .98 1.00 1.05 1.01
KLA/ATP .97 .94 1.03 1.02 1.00 .99 1.05
Wnt2b
KLA  ATP  ATP+KLA
 NM_009520 wingless related MMTV integration site 2b (Wnt2b), mRNA [NM_009520] KLA 1.04 1.03 .99 1.01 .95 1.02 .99
ATP .95 1.00 .95 .99 .97 1.03 1.01
KLA/ATP 1.02 .99 1.01 1.06 .99 .99 1.02
Wnt3
KLA  ATP  ATP+KLA
 NM_009521 wingless-related MMTV integration site 3 (Wnt3), mRNA [NM_009521] KLA 1.04 1.02 1.04 1.02 1.00 .99 1.00
ATP 1.03 .98 1.04 1.04 .96 1.00 1.02
KLA/ATP 1.03 .99 .98 1.03 1.04 .94 1.03
Wnt3a
KLA  ATP  ATP+KLA
 NM_009522 wingless-related MMTV integration site 3A (Wnt3a), mRNA [NM_009522] KLA 1.01 1.00 1.06 1.02 .99 1.02 .99
ATP .96 .97 1.05 1.04 1.02 1.02 1.04
KLA/ATP 1.02 1.03 .96 1.01 .99 1.06 1.00
Wnt4
KLA  ATP  ATP+KLA
 NM_009523 wingless-related MMTV integration site 4 (Wnt4), mRNA [NM_009523] KLA 1.01 1.01 .97 1.06 1.12 1.02 .93
ATP 1.02 1.06 1.03 1.02 1.00 1.02 .98
KLA/ATP .94 1.01 1.06 1.05 .96 .96 1.00
Wnt5a
KLA  ATP  ATP+KLA
 NM_009524 wingless-related MMTV integration site 5A (Wnt5a), mRNA [NM_009524] KLA .98 1.06 1.01 .96 1.03 1.02 1.07
ATP 1.01 .96 1.06 1.11 1.02 .97 1.03
KLA/ATP 1.05 .96 .96 1.04 1.12 1.06 .96
Wnt5b
KLA  ATP  ATP+KLA
 NM_009525 wingless-related MMTV integration site 5B (Wnt5b), mRNA [NM_009525] KLA 1.04 1.04 1.19 1.11 1.10 1.11 1.05
ATP 1.04 1.01 .95 1.01 .99 1.04 1.05
KLA/ATP 1.05 1.06 1.11 1.07 1.04 1.08 1.05
Wnt6
KLA  ATP  ATP+KLA
 M89800 gb|Mouse Wnt-6 mRNA, complete cds. [M89800] KLA 1.92 1.97 1.93 2.04 2.01 2.62 5.22
ATP .96 .97 1.07 1.03 .76 .94 1.18
KLA/ATP 2.04 1.91 1.96 1.72 1.40 1.31 2.45
Wnt6
KLA  ATP  ATP+KLA
 NM_009526 wingless-related MMTV integration site 6 (Wnt6), mRNA [NM_009526] KLA 2.83 2.51 2.19 2.74 2.92 3.01 5.82
ATP 1.01 .87 1.07 .77 .59 1.11 1.06
KLA/ATP 2.31 2.49 2.69 1.79 1.63 1.26 2.64
Wnt7a
KLA  ATP  ATP+KLA
 NM_009527 wingless-related MMTV integration site 7A (Wnt7a), mRNA [NM_009527] KLA .96 .92 .91 .99 .96 .98 .97
ATP 1.05 .95 .98 .98 1.03 .98 1.11
KLA/ATP .92 .89 .88 .97 1.01 1.04 1.01
Wnt7b
KLA  ATP  ATP+KLA
 NM_009528 wingless-related MMTV integration site 7B (Wnt7b), mRNA [NM_009528] KLA 1.06 1.09 .99 1.09 1.06 1.19 1.26
ATP .99 .98 1.02 1.08 1.02 1.11 1.54
KLA/ATP 1.02 1.01 .99 1.14 1.07 1.09 1.58
Wnt8a
KLA  ATP  ATP+KLA
 NM_009290 wingless-related MMTV integration site 8A (Wnt8a), mRNA [NM_009290] KLA .92 1.01 .99 1.00 1.06 1.01 1.04
ATP 1.00 1.01 1.01 1.04 1.00 1.06 1.05
KLA/ATP 1.07 1.05 .99 1.08 1.07 1.09 1.07
Wnt8b
KLA  ATP  ATP+KLA
 NM_011720 wingless related MMTV integration site 8b (Wnt8b), mRNA [NM_011720] KLA 1.00 1.00 .94 1.03 .98 .98 .97
ATP .99 1.01 1.01 1.01 1.05 1.04 1.03
KLA/ATP .98 1.03 1.00 1.01 .99 1.02 1.02
Wnt9a
KLA  ATP  ATP+KLA
 NM_139298 wingless-type MMTV integration site 9A (Wnt9a), mRNA [NM_139298] KLA .93 .95 .95 1.01 .96 .97 1.01
ATP 1.01 .98 1.01 1.08 1.43 1.02 1.44
KLA/ATP .94 .96 1.03 1.15 1.43 1.15 1.21
Wnt9b
KLA  ATP  ATP+KLA
 NM_011719 wingless-type MMTV integration site 9B (Wnt9b), mRNA [NM_011719] KLA .97 1.00 .94 1.00 .99 .97 1.02
ATP .96 1.02 1.05 .99 .92 1.11 1.08
KLA/ATP .97 .96 .99 .93 .96 1.03 .99